First WHO Global Forum on Medical Devices: context, outcomes, and future actions
First WHO Global Forum on Medical Devices: context, outcomes and future actions

9–11 September 2010
Bangkok, Thailand
### Acronyms and abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGIT</td>
<td>Advisory Group on Innovative Technology</td>
</tr>
<tr>
<td>AIDS</td>
<td>acquired immune deficiency syndrome</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>compact disc read-only memory</td>
</tr>
<tr>
<td>CPG</td>
<td>clinical practice guideline</td>
</tr>
<tr>
<td>DALY</td>
<td>disability-adjusted life year</td>
</tr>
<tr>
<td>DVD</td>
<td>digital video disc</td>
</tr>
<tr>
<td>GBD</td>
<td>global burden of disease</td>
</tr>
<tr>
<td>GHTF</td>
<td>Global Harmonization Task Force</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HTA</td>
<td>health technology assessment</td>
</tr>
<tr>
<td>HTAi</td>
<td>Health Technology Assessment International</td>
</tr>
<tr>
<td>HTM</td>
<td>health technology management</td>
</tr>
<tr>
<td>ICF</td>
<td>International Classification of Functioning, Disability and Health</td>
</tr>
<tr>
<td>IFMBE</td>
<td>International Federation for Medical and Biological Engineering</td>
</tr>
<tr>
<td>INAHTA</td>
<td>International Network of Agencies for Health Technology Assessment</td>
</tr>
<tr>
<td>ISO</td>
<td>International Organization for Standardization</td>
</tr>
<tr>
<td>LED</td>
<td>light-emitting diode</td>
</tr>
<tr>
<td>MDG</td>
<td>Millennium Development Goal</td>
</tr>
<tr>
<td>NGO</td>
<td>nongovernmental organization</td>
</tr>
<tr>
<td>SMS</td>
<td>short message service</td>
</tr>
<tr>
<td>TAGHT</td>
<td>Technical Advisory Group on Health Technologies</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
<tr>
<td>WHA</td>
<td>World Health Assembly</td>
</tr>
</tbody>
</table>
# Table of Contents

**Executive Summary**  
3

**Introduction**  
4  
Background  
4

**First WHO Global Forum on Medical Devices: the context**  
7  
World Health Assembly resolution WHA60.29  
7  
Priority Medical Devices project  
9  
Global Initiative on Health Technologies  
9

**First WHO Global Forum on Medical Devices: outcomes**  
15  
The details  
16  
Programme  
16  
Statistics  
16  
Recommendation process  
18

**First WHO Global Forum on Medical Devices: future actions**  
21  
Outcomes of the First WHO Global Forum on Medical Devices  
21  
First outcome: Recommended priority actions  
21  
Second outcome: Best practices, available resources, tools and guidelines compiled  
22  
Third outcome: Establishment of a network of interdisciplinary professionals  
24  
Second Global Forum on Medical Devices  
24

**Conclusion**  
25

**List of appendices**

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Welcome address by Abhisit Vejjajiva, Prime Minister of Thailand</td>
</tr>
<tr>
<td>B</td>
<td>Inauguration address by Dr Margaret Chan, Director-General of WHO</td>
</tr>
<tr>
<td>C</td>
<td>Participation in baseline country survey and/or WHO meetings</td>
</tr>
<tr>
<td>D</td>
<td>Organizing committees for the First WHO Global Forum on Medical Devices</td>
</tr>
<tr>
<td>E</td>
<td>Programme of the First WHO Global Forum on Medical Devices</td>
</tr>
<tr>
<td>F</td>
<td>List of participants of the First WHO Global Forum on Medical Devices</td>
</tr>
<tr>
<td>G</td>
<td>Participant feedback survey results</td>
</tr>
<tr>
<td>H</td>
<td>Voting results for the 42 proposed recommendations, by theme</td>
</tr>
<tr>
<td>I</td>
<td>All recommendations suggested by forum participants</td>
</tr>
<tr>
<td>J</td>
<td>Draft programme summary for the Second WHO Global Forum on Medical Devices</td>
</tr>
</tbody>
</table>
Boxes, figures and tables

Figure 1  Six building blocks of health systems  5
Figure 2  The four interconnected factors necessary to improve population health  5
Box 1  Resolution WHA60.29  7
Figure 3  Baseline Country Survey on Medical Devices survey submissions  10
Box 2  Summary of the Baseline Country Survey on Medical Devices  11
Box 3  First TAGHT meeting: April 2009, Geneva  12
Box 4  Second TAGHT meeting: November 2009, Rio de Janeiro  13
Box 5  Third TAGHT meeting: June 2010, Cairo  13
Box 6  First AGiT meeting: June 2009, Singapore  14
Box 7  Second AGiT meeting: April 2010, Copenhagen  14
Box 8  Objectives and expected outcomes of the First WHO Global Forum on Medical Devices  15
Box 9  Speaker, chair, and poster presenter country representation  17
Figure 4  Participants of the Global Forum by organizational category  17
Table 1  Sessions by theme  18
Table 2  The 42 proposed recommendations from the First WHO Global Forum on Medical Devices  19
Table 3  Short- and long-term actions planned for the 15 priority recommendations  21
Table 4  Reference documents in development  23
Executive Summary

Medical devices – health technologies that are not medicines, vaccines or clinical procedures – save lives, improve health and are indispensable for the prevention, diagnosis, treatment and management of all medical conditions, diseases, illnesses and disabilities. But medical devices need to be accessible, appropriate for different health-care settings and affordable to populations in need. Since the adoption of resolution WHA60.29 on health technologies (1) by the Sixtieth World Health Assembly in May 2007, WHO has been working with partners towards devising an agenda, action plan, tools and reference documents to increase access to appropriate health technologies, particularly medical devices, to achieve one of WHO’s strategic objectives of improving access, quality and use of medical products and health technologies.

Convened in Bangkok, Thailand, from 9-11 September 2010, the First WHO Global Forum on Medical Devices (2) built on previous work, knowledge and experience in this area, and was a pivotal point in advancing collaborative efforts to improve access to appropriate medical devices globally. Participants included high-level policy-makers from Member States, representatives from patients’ organizations, nongovernmental organizations, health professionals, researchers, academic institutions, professional organizations, biomedical engineering institutions, umbrella organizations in the medical devices industry, and UN organizations. Participants from 106 countries attended the three-day Global Forum to discuss and explore existing and potential challenges and opportunities for promoting access to innovative, appropriate, affordable and high quality medical devices. A crucial outcome of the Global Forum was a consensus on the priorities for future action, resulting in agreed recommendations.

This report, the First WHO Global Forum on Medical Devices: context, outcomes and future actions, briefly describes the intense activity in the medical device arena leading up to the Global Forum. It outlines and discusses the main outcomes of the Global Forum, and then consolidates the information to focus on future actions for achieving global access to appropriate medical devices, through better regulation, assessment and management processes.

It is proposed that the stakeholders implement all of the priority actions outlined in this report, ideally, before the Second WHO Global Forum on Medical Devices in 2012. The WHO commitment to health technologies, particularly medical devices, is permanent and steadfast and more priority actions will be identified and implemented along the way, as necessary.

In order to increase health coverage, have better health services, and best assist populations in need, it is necessary to make all stakeholders aware of the importance of decisions relating to the design, choice and use of appropriate, safe and effective medical devices, and to act accordingly. All stakeholders, whoever and wherever they are, are accountable for the success or failure of access to appropriate medical devices – a fundamental factor in improving the health of populations.
Introduction

In September 2010, over 300 participants from around the world gathered in Bangkok, Thailand, for the first ever WHO Global Forum on Medical Devices (2). The Global Forum built on three years of intense activity that followed the adoption of the first resolution on health technologies by the World Health Assembly (WHA) in May 2007 (WHA60.29). These activities included: regional meetings on health technology; a baseline country survey on medical devices; development of reference documents and tools on medical device regulations, assessment and management; and a search for innovative technologies for global health concerns. The Global Forum provided a platform for raising awareness of the importance of medical devices, identifying and planning for future, country-driven priorities, and galvanising global support for this crucial health systems component.

High-level policy-makers from 106 Member States (including representatives from United Nations (UN) and nongovernmental organizations (NGO), diverse health professionals from research and academia, as well as umbrella organizations in the medical devices industry), met for three days to learn, share and discuss a previously neglected area of huge importance to global health that requires increasing recognition in the future: access to appropriate, affordable, innovative, and high quality medical devices.

At the Global Forum’s inaugural address the Prime Minister of Thailand, Mr Abhisit Vejjajiva, called on delegates, scholars, industry members, representatives from international organizations and donors to jointly commit themselves to “building fairness and reducing inequity to ensure access to affordable, safe and effective medical devices, and to quality health care for all” (3, Appendix A). And in her opening speech the Director-General of WHO, Dr Margaret Chan, challenged participants to maintain the momentum emerging on medical devices following the adoption of the health technology resolution three years earlier: “We are here to help set the agenda for a more rational approach to the acquisition and use of medical devices in their full range of applications,” she said. “I believe you will agree: too many people are being excluded from the benefits of medical devices, and this is a challenge we need to address” (4, Appendix B).

The following section outlines the importance of medical devices and sets the scene for the remainder of this report.

Background

Health technologies are one of the six building blocks identified by WHO as essential for all health systems (along with financing, health workforce, information, service delivery and leadership/governance) (Figure 1). If one (or more) of these six components is missing or inadequate, health systems cannot function at the level necessary to improve the health of individuals and populations in a sustainable way.
Furthermore, health technologies have key implications for universal health coverage, for the way in which health care is provided based on individual and population needs, on sound governance and community participation, and on public health policies (Figure 2).

The overall purpose of medical devices – health technologies that are not medicines, vaccines or clinical procedures – is to save lives and improve health and the quality of life. Medical devices also have a crucial role in the prevention, diagnosis, treatment and management of all medical conditions, diseases, illnesses and disabilities. Assistive devices, in particular, are indispensable for rehabilitation and to enhance the functionality of people with disabilities.

The few years preceding the 2007 World Health Assembly were crucial for Member States to comment on the draft health technology resolution, initially presented by Mexico to the WHO Executive Board. During...
this period the WHO Secretariat prepared a grant proposal for a global initiative on health technologies that was then submitted to the Bill and Melinda Gates Foundation and signed in May 2008. Furthermore, the time was also used to reach an agreement with the Government of the Netherlands on the need for a study that focused on defining the Priority Medical Devices project and its research agenda.

These activities resulted in three outcomes that together enabled medical devices advocacy to reach a tipping point: 1) support for the Priority Medical Devices project (7) by the Government of the Netherlands; 2) support by the Bill and Melinda Gates Foundation for three years of intense global work on health technology policies and innovation; and, 3) acceptance by 194 Member States of the World Health Assembly health technology resolution (11), which commits Member States and the WHO Secretariat to specific actions on medical devices. Each of these activities also contributes to fulfillment of a specific WHO strategic objective, namely to improve access, quality and use of medical products and health technologies.
First WHO Global Forum on Medical Devices: the context

WHO has several initiatives related to health technologies. They are detailed separately below, but should be viewed together as an integrated response to the 2007 World Health Assembly health technology resolution, which addresses the urgent need to make health technologies, in particular medical devices, globally available, accessible, appropriate and affordable, in line with WHO strategic objective of improving access, quality and use of medical products.

World Health Assembly resolution WHA60.29

In May 2007, the Sixtieth World Health Assembly expressed concern about the waste of resources resulting from inappropriate investments in health technologies. In particular, many medical devices do not meet high-priority needs, are incompatible with existing infrastructures, are irrationally or incorrectly used, or do not function efficiently. In adopting resolution WHA60.29 on health technologies the World Health Assembly acknowledged the need: “to contain burgeoning costs by establishing priorities in the selection and acquisition of health technologies … on the basis of their impact on the burden of disease, and to ensure the effective use of resources through proper planning, assessment, acquisition and management” (1).

Box 1 lists resolution WHA60.29 action points for Member States and the WHO Secretariat.

### Box 1
Resolution WHA 60.29

**URGES Member States:**

1. to collect, verify, update and exchange information on health technologies in particular medical devices as an aid to their prioritization of needs and allocation of resources;
2. to formulate as appropriate national strategies and plans for the establishment of systems for the assessment, planning, procurement and management of health technologies in particular medical devices, in collaboration with personnel involved in health-technology assessment and biomedical engineering;
3. to draw up national or regional guidelines for good manufacturing and regulatory practices, to establish surveillance systems and other measures to ensure the quality, safety and efficacy of medical devices and where appropriate participate in international harmonization;
4. to establish where necessary regional and national institutions of health technology, and to collaborate and build partnerships with health-care providers, industry, patients’ associations and professional, scientific and technical organizations;
5. to collect information that interrelates medical devices, which deal with priority public health conditions at different levels of care and in various settings and environments, with the required infrastructure, procedures and reference tools;

**REQUESTS the Director-General:**

1. to work with interested Member States and WHO collaborating centres on the development in a transparent and evidence-based way of guidelines and tools, including norms, standards and a standardized glossary of definitions relating to health technologies in particular medical devices;
(2) to provide support to Member States where necessary in establishing mechanisms to assess national needs for health technologies in particular medical devices and to assure their availability and use;

(3) to develop methodological tools to support Member States in analysing their health technologies in particular medical devices needs and health-system prerequisites;

(4) to provide technical guidance and support to Member States where necessary in implementing policies on health technologies, in particular medical devices especially for priority diseases, according to different levels of care in developing countries;

(5) to work jointly with other organizations of the United Nations system, international organizations, academic institutions and professional bodies in order to provide support to Member States in the prioritization, selection and use of health technologies in particular medical devices;

(6) to establish and update regularly an evidence and web-based health technologies database to serve as a clearing house which will provide guidance on appropriate medical devices according to levels of care, setting, environment, and intended health intervention, tailored to the specific needs of country or region;

(7) to provide support to Member States with vulnerable health-care systems so as to identify and put in place appropriate health technologies in particular medical devices that facilitate access to quality services in primary health care;

(8) to report on implementation of this resolution to the Executive Board and the Sixty-second World Health Assembly through the Executive Board.

Other World Health Assembly resolutions of relevance to health technologies include:

1) **Resolution WHA58.28 (8)**. Adopted by the World Health Assembly in May 2005, this resolution on eHealth acknowledged: “eHealth is the cost-effective and secure use of information and communications technologies in support of health and health-related fields, including health-care services, health surveillance, health literature, and health education, knowledge and research,” and urged Member States to develop and implement eHealth technologies.

2) **Resolutions WHA60.30 (9) and WHA61.21 (10)**. Adopted by the World Health Assembly in May 2007, WHA60.30 requests the WHO Secretariat to prepare background documents and support the Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property for the purpose of elaborating a plan of action. Resolution WHA61.21 (adopted in May 2008), establishes a global strategy and plan of action that consists of eight elements designed to promote innovation, build capacity, improve access and mobilize resources.

3) **Resolution WHA62.12 (11)**. Adopted by the World Health Assembly in May 2009, this resolution on primary health care, including health systems strengthening, urges Member States: “to improve access to appropriate medicines, health products and technologies, all of which are required to support primary health care.”
Priority Medical Devices project

In 2007, with support from the Ministry of Health, Welfare and Sport of the Government of the Netherlands, WHO established the Priority Medical Devices project (7) to determine whether medical devices on the global market adequately meet the needs of health-care providers and patients throughout the world and, if not, to propose remedial action based on robust research. The project identified gaps in the availability of medical devices and highlighted obstacles that hinder the full use of medical devices as public health tools. A second objective was the development of a methodology for identifying the medical devices required to meet global public health needs. A third objective was to propose a possible research agenda for exploring how the gaps and obstacles that were identified could be addressed.

The Priority Medical Devices project developed a public health-based approach to medical devices. The first step in this approach identified the most important health problems: on a global level this meant using the WHO global burden of disease framework (12) and disease risk factor estimates. The second step referred to clinical guidelines to identify how health problems are best managed. And the third and final step linked the results of the first two steps to produce a list of key medical devices (an availability matrix) needed for the management of the identified high-burden conditions, at a given health-care level and in a given context. Further literature searches and qualitative research helped to identify challenges and possible solutions regarding selection and use of medical devices, as well as medical device innovation.

The findings of the Priority Medical Devices project are reported and discussed in the report Medical devices: managing the mismatch (13), which was launched at the Global Forum in September 2010.1

Global Initiative on Health Technologies

Established in March 2008 by the WHO Department of Essential Health Technologies with support from the Bill and Melinda Gates Foundation, the aim of the Global Initiative on Health Technologies is to help make the benefits of core health technologies available at an affordable price, particularly to communities in resource-limited settings, in order to effectively control important health problems.

The initiative arose from the recommendations of two global consultations on health technologies hosted by WHO in February and March 2007, and from World Health Assembly resolution WHA60.29 approved in May 2007. The meetings were attended by external experts, representatives of governments, NGOs, patient associations, manufacturer umbrella associations, external stakeholders, and representatives of WHO Regional Offices and clusters.

The initiative has two main objectives:

1) To challenge the international community to establish a framework for the development of National Health Technology Programmes that will impact the burden of disease and ensure effective use of resources; and
2) To challenge the business and scientific communities to identify and adapt “innovative technologies” that can have a significant impact on public health.

1 Full report and background papers are available at http://www.who.int/medical_devices/access/en/index.html
To date, through the Global Initiative on Health Technologies, WHO and partners, (representatives of Member States, NGOs, advisers and other stakeholders) have worked to:

- Implement a Baseline Country Survey on Medical Devices, to determine the needs;
- Update and develop guidelines and tools required for the procurement, regulation, assessment, management, maintenance, donation and use of medical devices for different health care facilities and clinical procedures;
- Launch a search for innovative technologies that address global health concerns (as described below) and select some particular technologies;
- Compile and publish an e-documentation centre on health technology\(^2\). To date there are more than 300 published documents available in their original language.

**Baseline country survey**

In December 2008, the need to have evidence based data and information regarding health technology at the country level led to the launch of the baseline country survey on medical devices (14). Consultations were made with Member States and regional advisers before delivery to the Ministries of Health of all Member States and Associate Members in February 2010.

The baseline country survey on medical devices was designed to determine the availability of policies, guidelines, standards and services for the assessment, management and regulation of health technology in Member States and Associate Members. It is WHO’s intention to use this data to determine the key areas for the development of health technology programmes in regions and countries which require support, as well as to share knowledge and information among the participating countries.

As of November 2010, 144 (out of 196) countries had supplied information in response to the 22 survey questions. See Figure 3 for the geographical distribution of country responses.

**Figure 3 Baseline Country Survey on Medical Devices survey submissions**

\(^{2}\) The e-documentation center is available at http://www.who.int/medical_devices
The results of the survey have provided useful information and a summary of the key results to date are shown in Box 2.

Box 2
Summary of the Baseline Country Survey on Medical Devices
Participation was distributed throughout the different regions with 39 responses from the WHO African Region, 29 from the WHO Region of the Americas, 10 from the WHO Eastern Mediterranean Region, 44 from the WHO European Region, 6 from the WHO South-East Asia Region, and 16 from the WHO Western Pacific Region. See Appendix C for a detailed list.

ALL 144 COUNTRIES
• National policy on health technology
  - 34% have a national policy as part of the national health programme or plan;
  - 9% have a separate policy for health technologies;
  - 74% of countries have a unit (at least of one individual) within the Ministry of Health that manages medical devices;
  - 66% of countries have an authority responsible for implementing and enforcing medical device specific product regulations;
  - 58% of countries carry out the procurement of their medical devices at national level.

• Donations
  - 15% of countries use WHO guidelines on health-care equipment donations;
  - 26% have developed national guidelines;
  - 58% do not have any guidelines.

• Technical specifications
  - 41% of countries have recommended technical specifications of medical devices to support procurement or donations.

• National list of approved medical devices
  - 29% of countries have a national list of approved medical devices for procurement or reimbursement. An additional 12% have one as a recommendation.

• Medical equipment management units
  - 76% of countries have a medical equipment management unit with professionally trained biomedical/clinical engineers or technicians at one or more levels (national, regional or hospital level).

• Availability of high cost medical devices
  - At least seven countries do not have any mammogram equipment;
  - 25 countries lack any type of radiation therapy.

3 Complete results are available at http://www.who.int/medical_devices/survey_preliminary_results/en/index.html
Guidelines and tools

To help define needs and develop necessary tools, a series of international meetings took place in 2009 and 2010. The participants included country representatives, regional advisers, experts, NGOs, international professional organizations and representatives of the medical device industry.

The Technical Advisory Group on Health Technologies (TAGHT) met three times (Geneva, April 2009; Rio de Janeiro, November 2009; and Cairo, June 2010) to further the activities of objective 1 of the Global Initiative on Health Technology. The summary of each meeting is outlined in Boxes 3, 4, and 5 while full reports are available on the WHO website.

Box 3
First TAGHT meeting: April 2009, Geneva
The purpose of this meeting was to review and analyse country experiences in order to better support Member States in developing, improving or enhancing effective national health technology policies, programmes and systems, particularly through the revision and update of existing tools or the development of new ones to address identified gaps. The recommendations of the meeting were followed up by a smaller group of selected experts who worked on the revision and update of existing tools and development of new ones, as required.

The meeting convened participants and observers from 10 countries (see Appendix C), the 25 members of the TAGHT, and staff from WHO headquarters and four of the six WHO Regional Offices.

LOW-INCOME COUNTRIES

Of the 49 low-income countries, 33 have participated in the survey.

- 33% have a national policy for health technology;
- 55% have an authority responsible for implementing and enforcing medical device regulations;
- 85% have a designated unit within the Ministry of Health at federal or national level that claims to technically manage medical devices.

5 Documents and tools will be posted on http://www.who.int/medical_devices/en/ when available
6 Full reports are available at http://www.who.int/medical_devices/events/en/index.html
**Box 4**  
**Second TAGHT meeting: November 2009, Rio de Janeiro**  
The specific meeting objectives were to update participants on the health technology management tools under development since April 2009; review the current challenges and strategies facing the pilot countries; and hold an interactive session for the group to present proposals for new tools based on information gathered from the earlier presentations and discussions. Progress reports on tools development were presented and discussed by working groups. Additionally, further gaps in required guidelines and tools were identified and new working groups were formed to create the additional guidelines and tools.

The meeting convened participants and observers from 22 countries (see Appendix C), 23 members of the TAGHT, four representatives from the medical device industry, and staff from WHO headquarters and five of the six WHO Regional Offices.

**Box 5**  
**Third TAGHT meeting: June 2010, Cairo**  
The main objectives of this meeting were to identify the key components of an action plan for the implementation of national essential health technology programmes and to measure the progress of the programme adoption; identify resources currently available, including tools developed by experts from the 1st and 2nd meetings but also additional resources that might support effective implementation; and develop a prototype tool to assist in identifying gaps in needs. The meeting resulted in the participating countries developing and presenting their action plans.

The meeting convened participants and observers from nine countries (see Appendix C), eight members of TAGHT, staff from WHO headquarters and four of the WHO Regional Offices.

**WHO call for innovative technologies**  
The Advisory Group on Innovative Technology (AGIT) met twice (Singapore, June 2009 and Copenhagen, April 2010) to further the activities related to objective 2 of the Global Initiative on Health Technology. The summary of each meeting is outlined in Boxes 6 and 7 while full reports are available on the WHO website.

By the January 2010 deadline for the call for innovative technologies, 84 submissions from 29 countries were received in two categories: 1) those that described potentially commercial products; and 2) those which were not yet in the commercialized stage. Of the final 15 technologies selected, eight were in the first category and seven in the second. Several of these innovative technologies were also featured in poster presentations at the Global Forum.

---


Box 6
First AGIT meeting: June 2009, Singapore

The first AGIT meeting reviewed and prioritized key health problems to be addressed in the WHO call for innovative technologies that address global health concerns. Presentations by the WHO Collaborating Centres were reviewed to identify key global health concerns that could be addressed by a call for innovative technologies, and to develop criteria for the selection of the innovative technologies.

The meeting convened 23 AGIT members, representatives from seven WHO Collaborating Centres, eight members of staff from WHO Regional Offices and headquarters, and eight observers from the medical device industry and other organizations.

Box 7
Second AGIT meeting: April 2010, Copenhagen

Participants of the second AGIT meeting assisted in the final selection of applications to the call for innovative technologies, to advise on dissemination strategies for the technologies selected and to provide recommendations regarding future calls.

The meeting participants split into groups to review a set of pre-selected applications and their potential publication on the WHO website. Consideration was also given to how the selection process would be communicated to applicants and the public. The meeting participants included 17 technical advisors, two representatives of WHO Collaborating Centres, six staff from WHO Regional Offices and four from WHO headquarters.

All of the initiatives and activities outlined above informed and influenced the agenda for the participatory discussions at the First WHO Global Forum on Medical Devices, an interactive event in which all delegates collectively identified priority actions to advance access to appropriate medical devices.
First WHO Global Forum on Medical Devices: outcomes

Convened in Bangkok, Thailand at the Plaza Athenee Hotel, from 9-11 September 2010, the goal of the First WHO Global Forum on Medical Devices was to mobilize stakeholders into action. The Global Forum provided the opportunity to share evidence, knowledge and experience to inform discussions on best practices and tools available for medical device evaluation, prioritization, regulation, assessment, management and research.

Building on all previous work, knowledge and experience in this area, the Global Forum was a pivotal point in furthering collaborative efforts to help improve:

- Incorporation and implementation of health technology policies into countries’ national health plans to increase access to, encourage more rational use, and select better quality, effective medical devices, including those related to high-burden diseases and public health priorities;
- Health technology assessment to make informed decisions on the priorities of medical devices for adequate and appropriate health care coverage;
- Regulation to guarantee safe and effective medical devices;
- Management of health technologies and more efficient use of resources.
- Staff training in assessment, regulation, management (including staff retention) and operation of medical devices;
- Awareness of the need for medical device innovation and the need to identify safe, effective and appropriate solutions that help to achieve the MDGs, reduce the global burden of disease, and improve the performance of health systems.

Box 8 shows the objectives and expected outcomes of the First WHO Global Forum on Medical Devices.

---

**Box 8**

**Objectives of the First WHO Global Forum on Medical Devices**

- Demonstrate evidence on the need for appropriate evaluation, prioritization, regulation, assessment, management and research strategies on medical devices;
- Share knowledge on available resources: guidelines, tools, strategies, policies and best practices at national and regional levels and determine related needs;
- Bring together policy makers, professional organizations, funding agencies and key stakeholders to foster interdisciplinary partnerships and cultivate the aim of reaching a common goal;
- Encourage research, development and demonstration of appropriate and affordable quality medical devices.

**Expected outcomes**

- Identification of actions that can be taken for the improvement in availability, accessibility, appropriate selection, assessment, regulation, management, safety and use of medical devices;
- Compilation of best practices, available resources, tools and guidelines on medical devices for integration into national health plans;
- Establishment of a network of interdisciplinary professionals who will continue to support the role of medical devices in health systems.
The steering committee of the Global Forum comprised representatives from WHO; the Ministry of Health, Welfare and Sport, the Netherlands; the Ministry of Public Health, Thailand; Health Technology Assessment International (HTAi); the International Federation for Medical and Biological Engineering (IFMBE) and the International Network of Agencies for Health Technology Assessment (INAHTA). In addition, the international organizing committee comprised almost 50 members, including consultants, representatives from WHO Collaborating Centres, UN agencies, international professional organizations, NGOs, and WHO staff from headquarters and Regional Offices. For more details on the members of committees, see Appendix D.

The details

Programme
Given the high expectations, range and number of topics, and anticipated outcomes of the Global Forum, the programme (15, Appendix E) was designed to facilitate as many topics and as much discussion as possible.

Sessions were categorized into five main areas: role of medical devices to improve health service delivery; safe, accessible and affordable medical devices; health technology assessment; health technology management; and medical device regulation, and included eight plenary sessions, 18 parallel sessions, two poster sessions, and four workshops. All sessions incorporated time for in-depth discussion and participants could immediately interact (e.g. ask questions, send comments, vote) using personal electronic conferencing devices provided to them.

Speakers’ and poster presentations, a webcast of the Global Forum, including plenary and parallel sessions, and the short film that opened the conference: The power and potential of medical devices is available on the WHO website.\(^1\)\(^2\)

Statistics
In response to 500 invitations, 310 participants (103 female, 207 male) from 106 countries (see Appendix C) attended the three days of the Global Forum, along with 50 speakers (19 female, 31 male), and 20 chairs (5 female, 15 male). Speakers and chairs came from low, middle and high-resource setting representing a total of 33 different countries while the 41 posters were presented by representatives from 24 countries. Box 9 lists the countries represented. Keynote speeches were made by the Prime Minister of Thailand and the WHO Director-General. Furthermore, the conference was attended by eight Ministers of Health (the Comoros, Iraq, Madagascar, the Republic of Moldova, Samoa, the Sudan, Tajikistan and Thailand), and seven vice-Ministers of Health (Angola, Japan, Mexico, the Federated States of Micronesia, Paraguay, Poland and the Syrian Arab Republic). Representatives from the International Atomic Energy Agency, the United Nations Children’s Fund, the United Nations Office for Project Services (UNOPS) and the World Bank participated in the conference, along with the Assistant Director-General of Health Systems and Services, the Regional Director of the WHO South-East Asia Region, the Director of Essential Health Technologies, Regional Advisors for Health Technologies and Technical Officers from WHO. See Appendix F for a complete list of participants.

\(^1\) Detailed programme information is available at http://www.who.int/medical_devices/gfmd/en/index.html

\(^2\) The short film is additionally available at http://www.youtube.com/watch?v=92wB8e8T8EY
Box 9
Speaker, chair, and poster presenter country representation

<table>
<thead>
<tr>
<th>Speakers and chairs</th>
<th>Speakers and chairs</th>
<th>Speakers and chairs</th>
<th>Speakers and chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>Lithuania</td>
<td>Tunisia</td>
<td>India</td>
</tr>
<tr>
<td>Belgium</td>
<td>Mexico</td>
<td>Uganda</td>
<td>Italy</td>
</tr>
<tr>
<td>Brazil</td>
<td>Netherlands</td>
<td>United Kingdom</td>
<td>Japan</td>
</tr>
<tr>
<td>Canada</td>
<td>Nigeria</td>
<td>United States</td>
<td>Jordan</td>
</tr>
<tr>
<td>China</td>
<td>Norway</td>
<td>New Zealand</td>
<td>Niger</td>
</tr>
<tr>
<td>Denmark</td>
<td>Pakistan</td>
<td>Ghana</td>
<td>Norway</td>
</tr>
<tr>
<td>Egypt</td>
<td>Poland</td>
<td>Germany</td>
<td>Peru</td>
</tr>
<tr>
<td>Germany</td>
<td>Singapore</td>
<td>India</td>
<td>Philippines</td>
</tr>
<tr>
<td>Ghana</td>
<td>South Africa</td>
<td>Spain</td>
<td>South Africa</td>
</tr>
<tr>
<td>Italy</td>
<td>Sudan</td>
<td>China</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Japan</td>
<td>Sweden</td>
<td>Colombia</td>
<td>United Republic of</td>
</tr>
<tr>
<td>Jordan</td>
<td>United Republic of</td>
<td>Cuba</td>
<td>Tanzania</td>
</tr>
<tr>
<td></td>
<td>Thailand</td>
<td>Ethiopia</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gambia</td>
<td>United States</td>
</tr>
</tbody>
</table>

Poster Presenters

Albania
Argentina
Brazil
Canada
China
Colombia
Cuba
Ethiopia
Germany
India
Indonesia
Japan
Jordan
New Zealand
Niger
Peru
Philippines
South Africa
Switzerland
United Republic of
Tanzania
United Kingdom
United States

Figure 4 depicts participant breakdown by organizational category. Please see Appendix G for results from the participant feedback survey, reflecting their opinions in regards to the overall structure of the Global Forum (content of interest, presenters knowledge, and interactivity).

Figure 4. Participants of the Global Forum by organizational category
Recommendation process

One of the key outcomes of the Global Forum was to give a consensus view on priority actions. In order to enable participant agreement, the organizers of the Global Forum implemented a rigorous process, as described below.

Each parallel session was opened by the session chair and a co-chair gave a brief presentation of the work done by WHO in the topic area. Speakers (one to three per parallel session) then gave their presentations followed by questions, comments, and recommendations from participants.

The co-chair noted all of the recommendations made by participants in each session (listed by theme in Table 1). A grand total of 122 recommendations for all of the sessions was generated. At the end of each session, the recommendations were presented on screen. In a first round of voting, session participants were asked to select those recommendations they thought were the most important. The three recommendations with the highest votes for each session were selected resulting in a total of 42 key recommendations (three were omitted due to duplication or conflict of interest). All meeting participants had a subsequent opportunity to take part in a second round of voting on the 42 key recommendations. The key recommendations with the most votes were selected for a final list of 15 priority recommendations.

Table 1. Sessions by theme

<table>
<thead>
<tr>
<th>Theme</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>The role of medical devices to improve health service</td>
<td>MDGs 4, 5 and 6</td>
</tr>
<tr>
<td>delivery</td>
<td>Meeting the needs</td>
</tr>
<tr>
<td></td>
<td>The convergence of eHealth and medical devices: implications for the</td>
</tr>
<tr>
<td></td>
<td>future</td>
</tr>
<tr>
<td>Safe, accessible and affordable medical devices</td>
<td>Towards safe and appropriate radiation treatment</td>
</tr>
<tr>
<td></td>
<td>Safe medical devices for the patient, the health worker and the</td>
</tr>
<tr>
<td></td>
<td>environment</td>
</tr>
<tr>
<td></td>
<td>WHO call for innovative technologies that address global health</td>
</tr>
<tr>
<td></td>
<td>concerns</td>
</tr>
<tr>
<td>Health technology assessment</td>
<td>Assessment for innovative and emerging technologies</td>
</tr>
<tr>
<td></td>
<td>Health technology assessment (HTA) of medical devices: national</td>
</tr>
<tr>
<td></td>
<td>prioritization processes</td>
</tr>
<tr>
<td></td>
<td>The need for continuous HTA in developing countries and the role of</td>
</tr>
<tr>
<td></td>
<td>international organizations</td>
</tr>
<tr>
<td>Health technology management</td>
<td>Equipment incorporation: selection, procurement and donations</td>
</tr>
<tr>
<td></td>
<td>Health-care technology operation: training, safe use and maintenance</td>
</tr>
<tr>
<td></td>
<td>Needs assessment: epidemiological needs, inventories and medical device</td>
</tr>
<tr>
<td></td>
<td>lists</td>
</tr>
<tr>
<td>Health technology regulation</td>
<td>The need for adverse event reporting and post-market surveillance</td>
</tr>
<tr>
<td></td>
<td>Pre-market approval including preclinical and clinical evaluation</td>
</tr>
<tr>
<td></td>
<td>Harmonization of regulation - challenges and benefits</td>
</tr>
</tbody>
</table>

Table 2 presents the 42 key recommendations and the overlap between the general voting and the in-session voting. The top three recommendations within each theme were chosen as the final 15 priority recommendations. Appendix H charts the results of the round 2 voting on the 42 recommendations and Appendix I lists all 122 recommendations suggested by the forum participants.

In the closing session of the Forum, Dr Carissa Etienne, WHO Assistant Director-General emphasized that the organization intends to take forward the priority recommendations, and to seriously consider all of the remainder recommendations – work that will be prioritized and presented at the Second WHO Global Forum on Medical Devices in 2012.

The priority recommendations are considered and discussed in the final section of this report.
Table 2. The 42 proposed recommendations from the First WHO Global Forum on Medical Devices

<table>
<thead>
<tr>
<th>Overall Ranking</th>
<th>Top recommend. in-session</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The role of medical devices to improve health service delivery</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>X</td>
<td>Promote culture of safety in developing countries by adverse event reporting and integrate patient safety concepts into the curriculum of medical professionals.</td>
</tr>
<tr>
<td>2</td>
<td>X</td>
<td>Highlight and share examples of appropriate technologies (locally produced, low prices, easy to use, durable and reliable) that succeeded in different national health care settings.</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>Use the infrastructure of teaching units and the guidelines already present for training of trainers and technicians on medical technologies.</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>Enhance knowledge base of disease epidemiology, solutions and cost-effectiveness.</td>
</tr>
<tr>
<td>5</td>
<td>X</td>
<td>Survey countries for successful/unsuccessful e-health/telemedicine projects.</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>Conduct cost-benefit studies.</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>Strengthen patient/community involvement in all medical devices processes (design, research, provision, etc.) to improve health outcomes and ensure that needs are met.</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>Establish links between government and NGO projects and programmes.</td>
</tr>
<tr>
<td><strong>Safe, accessible and affordable medical devices</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>X</td>
<td>Ensure that properly trained personnel are in place at the time of installation of radiation medicine technology.</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>Plan carefully at the government level for any new installation including consideration of proper infrastructure for effective use of the technology and investment in staff training.</td>
</tr>
<tr>
<td>3</td>
<td>X</td>
<td>Look at international recommendations to establish proper sharp waste management.</td>
</tr>
<tr>
<td>4</td>
<td>X</td>
<td>Facilitate the emergence of clear context-specific regulatory guidelines.</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>WHO: Continue producing technical specifications of medical devices and guidance on cost assessment.</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>WHO: Foster cooperation between academia and industry.</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>Member States: Find an appropriate way of phasing out the use of mercury.</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>Conduct evidence-based comparison between mercury and digital equipment.</td>
</tr>
<tr>
<td><strong>Health technology assessment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>WHO: Support developing countries to develop capacity, learning from countries with developed health technology assessment systems and considering different models.</td>
</tr>
<tr>
<td>2</td>
<td>X</td>
<td>WHO: Promote health technology assessment as an integral part of health system research and strengthening and assist developing countries in conducting health technology assessment.</td>
</tr>
<tr>
<td>3</td>
<td>X</td>
<td>WHO: Help Member States to identify tools for prioritizing devices by using the health technology assessment process.</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>Identify and adapt tool kits needed for health technology assessment and prioritize according to type, need and stage of development.</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>WHO and other international organizations: Use experience of developed countries to build local capacity focusing on transparency for assessing and purchasing.</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>Member States: Integrate continuous health technology assessment into the existing health system environment and health care system reforms.</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>Urge health technology assessment agencies to collaborate with developing countries.</td>
</tr>
<tr>
<td>8</td>
<td>X</td>
<td>WHO: Promote the value of continuous health technology assessment regarding medical devices in decisions to stakeholders in developing countries, policy-makers and industry representatives.</td>
</tr>
</tbody>
</table>
### Health technology management

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>WHO:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>X</td>
<td>Support free access to nomenclature systems.</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>X</td>
<td>Urge industry to tag medical devices with a nomenclature reference.</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>Develop tools for needs assessment incorporating multiple dimensions (e.g. human resources, epidemiology, etc.)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>Provide up-to-date medical device lists to be functional/procedure and facility level-based.</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>Develop toolkit for life cycle cost of equipment and standardization of equipment.</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>Provide case studies to show evidence of effectiveness of health technology management.</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>X</td>
<td>Develop decision-making guideline and tools to determine requirements for needs-driven procurement of technologies.</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>Develop and/or enhance training facilities for health technology managers.</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>Support and enhance the profile of health technology management and structures within ministries of health.</td>
<td></td>
</tr>
</tbody>
</table>

### Health technology regulation

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>WHO:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>X</td>
<td>Facilitate opportunities for capacity building based on cooperation between regulatory authorities.</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>Facilitate capacity building for post-market surveillance and adverse event reporting in low-income countries.</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>Promote an exchange system for information on regulatory action.</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>WHO and Global Harmonization Task Force (GHTF): Support governments to have harmonized standards in different countries.</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>Facilitate experience sharing and a meeting for device regulators every two years.</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>X</td>
<td>Encourage international databank for adverse events in addition to national databases and exchange of information.</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>X</td>
<td>WHO and GHTF: Take lead in the use of medical device regulation for pre-market and post-market guidance.</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>Promote more support to assist countries to develop harmonized mechanisms.</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>Develop a programme for adverse event reporting on medical devices.</td>
<td></td>
</tr>
</tbody>
</table>
First WHO Global Forum on Medical Devices: future actions

Under the auspices of WHO, there have been three years of intense work on medical devices conducted by various groups, committees and individuals, culminating in the First WHO Global Forum on Medical Devices. The final section of this report highlights the need for an integrated action plan that takes into account all of the WHO collaborative work in health technology.

Outcomes of the First WHO Global Forum on Medical Devices

First outcome: Recommended priority actions

In response to each of the 15 priority recommendations agreed by Global Forum participants, short- and long-term actions were developed (see Table 3) through discussion with the six WHO Regional Advisers on health technology.

Table 3. Short- and long-term actions planned for the 15 priority recommendations

|-----|----------------|-----------------------------------|---------------------------------------------|
| 1   | Promote culture of safety in developing countries by adverse event reporting and integrate patient safety concepts into the curriculum of medical professionals. | - WHO medical devices unit to link with patient safety related units within WHO.  
- WHO to disseminate WHO Patient Safety Curriculum Guide for Medical Schools. | - WHO to work with internal and external partners to improve post-market surveillance, adverse event reporting and technology-related patient safety issues. |
| 2   | Highlight and share examples of appropriate technologies (locally produced, low prices, easy to use, durable and reliable) that succeeded in different national health care settings. | - WHO to make available on website a list of examples of appropriate/innovative technologies along with links to other relevant organizations. | - WHO to map the WHO list of innovative technologies to the research agenda of the Priority Medical Devices project.  
- Collaborating centers to test the “propriateness” of innovative technologies by region and create a database of the results. |
| 3   | Use the infrastructure of teaching units and the guidelines already present for training of trainers and technicians on medical technologies. | - WHO to post a database of biomedical engineering related university programs and professional societies on WHO website. | - WHO to send information, recommendations and guidelines to all universities included in the database. |

Safe, accessible and affordable medical devices:

| 4   | Ensure that properly trained personnel are in place at the time of installation of radiation medicine technology. | - WHO medical devices unit to work with the radiation safety unit at WHO, International Atomic Energy Agency (IAEA) and professional organizations, such as the International Organization for Medical Physics (IOMP) to disseminate radiation guidelines. | - WHO to work with IAEA and other organizations on medical imaging and radiation capacity building, including the safe use and installation of medical radiation technologies. |
| 5   | Plan carefully at the government level for any new installation including consideration of proper infrastructure for effective use of the technology and investment in staff training. | - WHO to develop a needs assessment tool. | - WHO to facilitate the implementation of the needs assessment process (thereby enabling better planning) at the country level. |
| 6   | Look at international recommendations to establish proper sharp waste management. | - WHO to disseminate tools and guidelines on sharps waste management via health technology focal points in member states, industry, patient organizations and academia. | - WHO to assist countries in developing and implementing strategies on sound health-care waste management. |
### Health technology assessment (HTA)

<table>
<thead>
<tr>
<th></th>
<th>WHO: Support free access to nomenclature systems.</th>
<th>WHO: Support developing countries to develop capacity, learning from countries with developed health technology assessment systems and considering different models.</th>
<th>WHO: to develop health technology assessment tool. - WHO to provide information regarding HTA on their website with links to collaborating centres and other institutions with which WHO shares a MoU in order to support access to information.</th>
<th>WHO: to support the development of HTA units at the Ministry of Health through the exchange of information and best practices from existing health technology agencies. - WHO: to coordinate workshops on how to develop HTA such that HTA is included as a tool for decision making.</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td></td>
<td></td>
<td>- WHO to develop health technology assessment tool. - WHO to provide information regarding HTA on their website with links to collaborating centres and other institutions with which WHO shares a MoU in order to support access to information.</td>
<td>WHO: to support the development of HTA units at the Ministry of Health through the exchange of information and best practices from existing health technology agencies. - WHO: to coordinate workshops on how to develop HTA such that HTA is included as a tool for decision making.</td>
</tr>
<tr>
<td>8</td>
<td>WHO: Promote health technology assessment as an integral part of health system research and strengthening, and assist developing countries in conducting health technology assessment.</td>
<td>- WHO to disseminate the use of existing tool kits that will assist newly formed HTA agencies/units in conducting a health technology assessment.</td>
<td>- WHO: to coordinate workshops that will enable newly formed HTA agencies/units to develop recommendations and establish priorities.</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>WHO: Help Member States to identify tools for prioritizing devices by using the health technology assessment process.</td>
<td>- WHO to disseminate the use of existing tool kits that will assist newly formed HTA agencies/units in conducting a health technology assessment.</td>
<td>- WHO: to coordinate workshops that will enable newly formed HTA agencies/units to develop recommendations and establish priorities.</td>
<td></td>
</tr>
</tbody>
</table>

### Health technology management

<table>
<thead>
<tr>
<th></th>
<th>WHO: Support free access to nomenclature systems.</th>
<th>WHO: Support free access to nomenclature systems.</th>
<th>WHO: to develop the ideal characteristics of a nomenclature system to share with key stakeholders in order to define a single medical devices nomenclature system.</th>
<th>WHO: to work with external organizations and come to a consensus on selecting or creating a single WHO nomenclature system.</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>WHO: Urge industry to tag medical devices with a nomenclature reference.</td>
<td>WHO: Urge industry to tag medical devices with a nomenclature reference.</td>
<td>WHO: to compare the information available on unique identification numbers.</td>
<td>WHO: to work with all stakeholders, including industry to select the best method to tag medical devices.</td>
</tr>
<tr>
<td>12</td>
<td>WHO: Develop tools for needs assessment incorporating multiple dimensions (e.g. human resources, epidemiology, etc.).</td>
<td>WHO: Develop tools for needs assessment incorporating multiple dimensions (e.g. human resources, epidemiology, etc.).</td>
<td>WHO: to develop a needs assessment tool.</td>
<td>WHO: to facilitate the implementation of the needs assessment process (thereby enabling better planning) at the country level.</td>
</tr>
</tbody>
</table>

### Health technology regulation

<table>
<thead>
<tr>
<th></th>
<th>WHO: Facilitate opportunities for capacity building based on cooperation between regulatory authorities.</th>
<th>WHO: Facilitate opportunities for capacity building based on cooperation between regulatory authorities.</th>
<th>WHO: to update the regulations guideline in 2011.</th>
<th>WHO: to update information relating to regulation on the WHO website. - WHO: to promote collaboration between regulators. - WHO: to coordinate regional workshops on the topic of regulation.</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>WHO: Facilitate opportunities for capacity building based on cooperation between regulatory authorities.</td>
<td>WHO: Facilitate opportunities for capacity building based on cooperation between regulatory authorities.</td>
<td>WHO: to update the regulations guideline in 2011.</td>
<td>WHO: to update information relating to regulation on the WHO website. - WHO: to promote collaboration between regulators. - WHO: to coordinate regional workshops on the topic of regulation.</td>
</tr>
<tr>
<td>15</td>
<td>Promote an exchange system for information on regulatory action.</td>
<td>Promote an exchange system for information on regulatory action.</td>
<td>- WHO: to review existing adverse event reporting and post-market surveillance systems for the eventual selection of one system. - WHO: to make available links to adverse event reporting and post market surveillance information as well as regulatory action taken on their website.</td>
<td>WHO: to provide guidelines, tools and capacity building for adverse event reporting and post-market surveillance. - WHO: to select one system for adverse event reporting and post-market surveillance.</td>
</tr>
<tr>
<td>14</td>
<td>WHO: Facilitate capacity building for post-market surveillance and adverse event reporting in low-income countries.</td>
<td>WHO: Facilitate capacity building for post-market surveillance and adverse event reporting in low-income countries.</td>
<td>- WHO: to review existing adverse event reporting and post-market surveillance systems for the eventual selection of one system. - WHO: to make available links to adverse event reporting and post-market surveillance information as well as regulatory action taken on their website.</td>
<td>WHO: to provide guidelines, tools and capacity building for adverse event reporting and post-market surveillance. - WHO: to select one system for adverse event reporting and post-market surveillance.</td>
</tr>
</tbody>
</table>

### Second outcome: Best practices, available resources, tools and guidelines compiled

The Priority Medical Devices project and the work done under the auspices of the Global Initiative on Health Technologies identified some best practices. Similarly, during the course of the Global Forum, participants shared their experiences, successes and challenges. This information will be published in a best practice compilation. Both the Priority Medical Devices project and the Global Initiative on Health Technologies developed a public health approach to medical devices and identified the need to focus on the availability, accessibility, appropriateness and affordability of medical devices - concepts discussed at the Global Forum and overwhelmingly supported by participants. Inclusion of accountability in this list of “A’s” was proposed in the final session of the Global Forum.

For the purposes of knowledge sharing, detailed information on medical devices presented in the Priority Medical Device project’s eight background papers was also included in the CD-ROM given to conference participants and widely disseminated. This information is available through a dynamic e-resource library, which includes documents on best practices, available resources, tools and reference documents on medical devices for integration into national health plans. As a result of the Global Forum, this e-resource,
the “WHO health technologies e-documentation center”, has become a more comprehensive source of information to best suit the needs of those who use this service1.

Furthermore, information from the Baseline Country Survey on Medical Devices (14) has provided valuable insight into the current situation regarding medical devices in individual countries. In addition to providing essential information, the results of the survey have served as a needs assessment to better inform all stakeholders about priority areas for action, which have been included in the Global Forum recommendations. Information provided by this ongoing survey will be included in each country profile on the WHO website and will be used as a benchmark to help decision-makers and encourage country action at the national, regional and global levels.

The collaborative work of the Global Initiative on Health Technology has involved developing tools to integrate appropriate and affordable medical devices into the health system delivery component of national health plans, in order to reach universal health coverage. Some of these tools were discussed in the parallel sessions of the Global Forum and have been included in the final recommendations agreed by all participants.

In addition, members of the TAGHT have also been working to update and revise guidelines on the regulation, assessment, donations, procurement, maintenance, policies, management and use of medical devices (see Table 4). This work has also focused on developing lists of medical devices by clinical practice guidelines and by health-care facilities. The draft guidelines were presented for consultation on the CD-ROM given to Global Forum participants and also discussed during the course of the meeting. WHO will publish these reference documents in 2011.

Table 4. Reference documents in development

<table>
<thead>
<tr>
<th>No.</th>
<th>Subject area</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Health technology assessment</td>
</tr>
<tr>
<td>2</td>
<td>Medical device regulations</td>
</tr>
<tr>
<td>3</td>
<td>Needs assessment</td>
</tr>
<tr>
<td>4</td>
<td>Medical device procurement</td>
</tr>
<tr>
<td>5</td>
<td>Guidelines for health-care equipment donations</td>
</tr>
<tr>
<td>6</td>
<td>Health-care equipment maintenance</td>
</tr>
<tr>
<td>7</td>
<td>Health-care equipment inventory management</td>
</tr>
<tr>
<td>8</td>
<td>Computerized Maintenance Management System</td>
</tr>
<tr>
<td>9</td>
<td>Policy framework for health technology management</td>
</tr>
<tr>
<td>10</td>
<td>Medical devices nomenclature</td>
</tr>
<tr>
<td>11</td>
<td>Medical devices by health-care setting</td>
</tr>
<tr>
<td>12</td>
<td>Medical devices by clinical practice guidelines</td>
</tr>
</tbody>
</table>

1 The e-documentation center is available at http://www.who.int/medical_devices
Third outcome: Establishment of a network of interdisciplinary professionals
To date, many countries, organizations, groups and individuals from different sectors, have been involved in and helped to inform and develop all of the WHO collaborative work on medical devices. This has resulted in several networks of stakeholders including: the TAGHT; the AGIT; the Advisory Group and Steering Committee of the Priority Medical Devices project; and the Steering Committee and International Organizing Committee of the Global Forum. In addition, WHO has established four email listservs (focusing on eHealth, health technology assessment, regulation, and health technology management) and an online community for health technology focal points in 144 countries. Furthermore, participants at the Global Forum and those who were interested in attending, were invited to join the aforementioned listservs after the Global Forum.

Second Global Forum on Medical Devices
The Second WHO Global Forum on Medical Devices is planned for 2012. Participants will share progress made on all activities to date related to the 15 priority recommendations and the implementation of resolution WHA60.29 on health technologies as well as decide on additional priority actions. See Appendix J for a draft programme summary.
Conclusion

In some countries, action to improve access to health technologies began more than 20 years ago, but in many others such action has only recently started. The Global Initiative on Health Technologies, resolution WHA60.29 on health technologies, the Priority Medical Devices project and the First WHO Global Forum on Medical Devices have all helped raise awareness of the need for affordable, appropriate, accessible and available medical devices – and as discussed at the Global Forum, the need for a robust accountability process.

All stakeholders are invited to implement the actions outlined in this report (with particular emphasis on the regulation, assessment and rational management of medical devices, the use of appropriate and innovative technologies, and implementation of a public health approach to medical devices) before the Second Global Forum on Medical Devices in 2012. At this event, a new and updated action plan for the next steps towards ensuring adequate access to safe, effective and appropriate medical devices in health systems in all countries will be reviewed and discussed. Presentations on the implementation of resolution WHA60.29 on health technologies, 5 years after its approval, will be given by stakeholders and Member States. Additionally, more action points will be identified and implementation plans developed, as necessary.

In order to adequately address the important role of medical devices in the management of high-burden health problems and in health system strengthening, continuous action, targeted advocacy, fundraising, donor support and strong leadership are all essential. Men, women, children and newborns should not continue to die or suffer because the medical devices required to save their lives or improve their quality of life remain unavailable, inaccessible, inappropriate or unaffordable. For the sake of the health of poorer and all populations, we must not waste time: we have to act together – now.
References


Appendix A

Welcome address by Abhisit Vejjajiva, Prime Minister of Thailand

His Excellency Abhisit Vejjajiva
Prime Minister of Thailand

Inauguration address at the First WHO Global Forum on Medical Devices
Bangkok, Thailand
9 September 2010

Your Excellency Dr. Margaret Chan,
Director General of the World Health Organisation,
Your Excellencies the Ministers of Health, honourable guests, ladies and gentlemen,

1. On behalf of the Royal Thai Government and people of Thailand, I would like to welcome all of you to Thailand for the First Global Forum on Medical Devices. I am honoured to be with you at this distinguished gathering of delegates from Member States of the World Health Organisation, as well as scholars and representatives of health professions, international agencies, civil society organisations, and the industry.

2. Protecting the health of the population is a crucial responsibility of all governments. Healthy people are every nation’s valuable assets, as a productive workforce drives forward the economy. More importantly, having a healthy state of the body and the mind is a fundamental right of everyone in every society. As defined by the World Health Organisation, “health” is “a state of complete physical, mental and social well-being, and not merely the absence of disease or infirmity”. Ensuring people’s health clearly requires the collaborative efforts of various sectors in society, as well as the global community. Moreover, in today’s medical care, medical technology and devices have assumed increased importance, in the quality and cost of healthcare services.

3. I am therefore very glad that this First Global Forum on Medical Devices is being held in Thailand. I am also pleased to learn that all of you who are gathered here are dedicated policymakers, officials, practitioners and experts from organisations in different sectors around the world, who are ready to share your knowledge and expertise, as well as your wealth of experiences, in our collective efforts to address the needs for appropriate policies and systems concerning medical devices.

4. The value of this kind of exchange cannot be exaggerated. Deliberations, discussions and lessons learned in various international conferences in the past have enhanced awareness of existing problems, generated new ideas, inspired proper solutions, and led to the undertaking of actions amongst policymakers and other key stakeholders in different countries. With your contributions, I am confident that this Forum will be recognised as a crucial milestone in health policy development at both national and international levels.

Excellencies,

Distinguished Participants,
5. The issue of medical devices and equipment is not a stand-alone issue. As a means to promote people’s health, these technologies are normally introduced in the healthcare systems, while some of them are used by households, on a self-care basis. Therefore, in most instances, it is difficult to address problems related to medical devices and other health technologies without taking into account the culture, infrastructure and other characteristics of the health systems in particular countries. In the same vein, in making essential medical devices available to the population in need of them at affordable prices, it is important to consider this effort in the global and national contexts, where issues relating to research and development and production capacity, technology transfer, and trade regulations are also involved.

6. In this connection, I would like to commend the organising committee of this conference for incorporating all important aspects of medical devices – including innovation, prioritization, regulation, evaluation, procurement, usage, and so on – into the meeting agenda. It is also important that this conference will touch upon many topics particularly relevant to low- and middle-income countries, as well as policy issues that are relevant in any setting, regardless of the country’s economic status.

7. I wish to highlight here two issues, namely, “universal access” and “equity”, where lessons can be drawn from Thailand’s health system. The Thai Constitution recognises access to health care as a basic right of all Thais, and thus our universal health coverage plan was established in 2002. We learn, however, that despite strong political commitments and multi-sectoral efforts, translating these policies into actions, and achieving equitable access to health services in practice, is not easy. Limited resources have compelled us to find ways to allocate and use them efficiently. Technology assessment, selection and management, including bulk purchasing, are among effective solutions adopted at the national level and in hospitals. The unaffordable price of healthcare products, which are, in some instances, associated with patents, is also an important barrier to their accessibility. I am delighted that the issues of ‘Intellectual Property and Innovation’ and ‘Technology Transfer’ will be discussed in this Forum, which will help improve access to a number of essential medical devices.

8. To reaffirm the importance of universal health coverage, I would like to call upon distinguished delegates, scholars, industry members, representatives from international organisations and donors to jointly commit themselves to “building fairness and reducing inequity” to ensure access to affordable, safe and effective medical devices, and to quality health care for all.

9. There are other challenges we must confront. The first one is the so-called issue of ‘rational’ versus ‘irrational’ use of medical devices and public education on this issue. Irrational use of medical devices has resulted in high costs without reasonable health gains. Policy decisions need to be supported by evidence proving the “value for money” of medical devices. Thus, it is fundamental to build up adequate capacity on Health Technology Assessment in our countries. Another challenge involves regulation. Like medicines, medical devices should be cost-effective, efficacious, safe and of good quality---hence every country needs to develop strong regulatory structures to ensure that these requirements are met. At the same time, systems should be established for the safe and effective disposal of outdated or expired medical devices that may pose risk for users. The last challenge is the strengthening of R&D and manufacturing of medical devices in developing countries, so that their citizens can access the technologies they need at affordable prices. I fully support the initiative to tackle all of these challenges, and to jointly build upon our strengths.
10. As well-devised health policies alone do not guarantee equitable access to quality services and essential technologies, it is my hope that this meeting will create fertile grounds for future networks and cooperation to strengthen policy development and implementation capacity with regard to medical devices, amongst Member States and domestic and international institutions.

11. Here in Thailand, we have long been addressing the need for multi-sectoral and interorganisational integration of health policies, as well as public-private partnership in order to efficiently tackle major health issues. I am certain that the lessons learned and experiences shared in this conference will be very helpful to all countries. For Thailand, our commitment is to see the establishment of the National Medical Device Systems Development Committee.

12. In closing, I wish to express my deep appreciation to the World Health Organisation, Madam Director General and her team for having taken the initiative in convening this Conference, and in providing Thailand with the opportunity to take on the important role as co-host. I wish all participants an enjoyable stay in Thailand, and great success in the meeting's deliberations. Thank you very much and Sawasdee Krub.

Appendix B

Inauguration address by Dr. Margaret Chan, Director-General of WHO
Medical devices: an area of great promise

Dr Margaret Chan
Director-General of the World Health Organization

Opening address at the Global Forum on Medical Devices
Bangkok, Thailand
9 September 2010

Your Excellency, Prime Minister Abhisit, honourable ministers, distinguished delegates, representatives of professional societies, patient groups, and industry, ladies and gentlemen,

I am pleased to welcome you to this first Global Forum on Medical Devices. I thank the government of Thailand and its Ministry of Public Health for hosting and supporting this event.

You represent a diversity of disciplines, interests, and country experiences. This diversity is important given the complexity of the task before us. This is the first meeting of its kind, and you will be exploring some new territory where the best way forward for public health is largely uncharted.

The field of medical devices is large, diverse, competitive, and highly innovative. This is an area of great promise, sometimes spectacular promise, sometimes seductive promise. It is also an area with a number of problems and pitfalls, some familiar, others unique.

As many have noted, the field of medical devices requires, and deserves, its own unique agenda. Health officials and hospital managers in all countries, at all levels of development, need guidance.

The medical devices industry produces high-tech high-cost diagnostic and therapeutic equipment, but it also produces the basic supplies and devices that keep any health facility running smoothly on a daily basis.

The field also includes devices that aid functional ability, like wheelchairs, hearing aids, eyeglasses, intraocular lenses, and artificial limbs. The vital role of such devices in improving the quality of life is obvious, though often overshadowed by the attention given to more spectacular devices.

We are here to help set the agenda for a more rational approach to the acquisition and use of medical devices in their full range of applications.

We are here, in part, because of concern about runaway health care costs and pressure to contain these costs. As noted in a 2007 World Health Assembly resolution, health technologies, and medical devices in particular, represent an economic as well as a technical challenge to health systems.

That resolution expressed concern about the waste of resources caused by investments in medical devices that do not meet high-priority needs, are incompatible with existing infrastructures, are irrationally or incorrectly used, or do not function efficiently. This tells us some of the pitfalls.
But we are also here because the unquestionable benefits of medical devices are so unevenly distributed. I wonder if there is any other area that illustrates so profoundly the great difference in the ability of wealthy and developing countries to reap the benefits of advances in medicine and technology.

As one example, a recent WHO survey showed that the availability of mammography, an important screening tool for breast cancer, is one per 47,000 people in high-income countries, but one per 5.7 million people in low-income countries. The availability of CT scanners is one per 170,000 people in high-income countries, but one per 3.8 million in low-income countries.

In some countries, shortages of needles, syringes, and sterilizing equipment mean that up to 40% of injections are unsafe. As yet another example, some 30 developing countries do not possess a single radiotherapy machine for cancer treatment.

I believe you will agree: too many people are being excluded from the benefits of medical devices, and this is a challenge we need to address.

I can suggest some reasons for this great imbalance.

The most obvious one concerns resources and costs. Technological advances nearly always come at a price higher than conventional technologies, and some medical devices are obviously priced for the financially privileged few.

One figure illustrates the magnitude of the affordability problem. Worldwide, annual government expenditure on health ranges from well over $7,000 per person to less than $10. Low levels of expenditure on health help explain why many medical devices are considered luxuries.

Yet high cost alone is not the only explanation, the only excuse for such inequitable access. Many badly needed and affordable devices, like electrocardiographs, are still not widely used in low-income settings. This may reflect how priorities are set, with medicines and vaccines having a higher place in budgets.

A second problem is inherent to the industry. These are medical devices, produced for a medical market, largely focused on financially profitable diseases, and almost exclusively designed for use in wealthy settings.

Currently, most medical equipment used in low-resource settings is imported from industrialized countries. About 70% of the more complex devices do not function when they reach their destination.

A third problem follows logically and is deeply familiar: lack of capacity. I mean lack of infrastructure and funds for recurring costs. I mean erratic power supplies, uncertain water quality, a crippling shortage of health personnel, limited training capacity, difficulties getting spare parts, and limited budgets for maintenance and for purchasing consumables.

Under such conditions, a technological miracle can rapidly become the worst nightmare of service providers: wasted resources and risks to patient safety.

Faced with such harsh realities, we need to ask: what does a true “cutting edge” technology mean for the developing world?
The biggest breakthroughs are likely to come with technologies that use alternative power supplies, resist heat, humidity, and dust, relieve the workload, require little maintenance, and can be operated, with no risk to patient safety, by personnel with little specialized training.

Or with something so simple as glucose meters and test strips that perform well in the hot and humid homes of diabetes patients. Or with robust portable machines that extend the advantages of technology beyond the hospital setting or take it from cities to rural areas.

This is a challenge, but not an insurmountable one. During outbreaks, WHO has seen how portable PCR machines can vastly increase the speed and precision of containment operations.

You will be discussing technology transfer, which can help, and donations, which can be problematic. Developing countries are littered with unused, obsolete equipment and devices. Recent studies suggest that only 10% to 30% of donated equipment ever becomes operational.

A fourth reason is possibly the most important. That is, a failure to look at this rapidly evolving industry from a public health perspective. When we take a public health perspective, one priority is clear. First take care of the basics.

If we think about the health-related MDGs, and about what hinders progress, it becomes easier to define some basic needs. Blood transfusion services to prevent women in labour from bleeding to death. Anaesthesia machines, oxygen bags, and basic surgical equipment. Rapid point-of-care diagnostics for malaria and tuberculosis. Resuscitation equipment for newborns with breathing problems. Generators that keep equipment running when the electrical power shuts down.

I know you will be discussing MDG-related issues during the meeting, and will have many other ideas and experiences to contribute.

And we have another big-picture issue we need to address. Though resources available to invest in medical devices are vastly different, the main health problems facing wealthy and developing countries are becoming remarkably similar.

I am referring in particular to the rise of chronic diseases, like cardiovascular disease, stroke, cancers, and diabetes. Once associated with affluence, these diseases now impose their heaviest burden on poor and disadvantaged populations. This shift in the disease burden clearly demonstrates the need for fairness in access to medical devices, including those appropriate and affordable for long-term care.

Ladies and gentlemen,

You are tasked with setting an agenda for a more rational approach to medical devices. This is not an easy task.

It is tempting to seek guidance from years of largely successful efforts to rationalize the use of pharmaceutical products.
We can certainly draw some guiding principles from experience with essential medicines, namely the importance of focusing on priority health needs, and on affordable devices that match those needs. We can certainly repeat the commitment to fair and equitable access.

We can also identify some similar obstacles that limit the appropriateness of medical devices to priority needs in the developing world. Market forces, all by themselves, will not automatically shift the R&D agenda for medical devices towards unmet needs in the developing world.

As with pharmaceutical products, explicit policies are needed to move the power of innovation more directly into the service of international health development.

But here the similarities end. The diversity of medical devices is much greater than that of medicines. The pace of new product development is faster, and the lifecycle of some medical devices can be as short as 18 months.

The regulatory pathways are different. The approval process for medical devices is often less rigorous. Factors affecting the safety of medical devices are more numerous, including the competence and skills of product users. The potential for human error when a person swallows a pill is quite different from that when staff operate highly complex equipment.

Systems for reporting adverse medical device events and for conducting post-marketing surveillance are not yet so well advanced. These, too, are pitfalls in the midst of great promise.

Despite the challenges, a key achievement of this meeting is its strong public health approach. The organizing and steering committees have put together a public health agenda. The agenda is firmly focused on needs assessment and improved access to priority devices, especially in low-resource settings.

You will be considering the potential of these devices to reduce gaps in health outcomes, to relieve some of the pressures of the workforce crisis, to improve service delivery, and to strengthen health systems.

You will take a close look at the enabling environment: the role of health technology assessment, the management of medical devices through national health plans and strategies, and the need for strong regulation and enforcement.

You will explore the convergence of advances in information and communication technologies with advances in medical technologies. As practical guidance, you will consider a process of priority setting at the national level and look for ways to harmonize regulatory pathways.

Ladies and gentlemen,

Medical devices require, and deserve, their own unique agenda. I wish you a most productive meeting.

Thank you.
## Appendix C
### Participation in baseline country survey and/or WHO meetings

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Algeria</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Angola</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Benin</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Botswana</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Burundi</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cameroon</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cape Verde</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Chad</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Comoros</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Congo</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Côte d’Ivoire</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Democratic Republic of the Congo</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Equatorial Guinea</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Eritrea</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Gabon</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Gambia</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Ghana</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Guinea</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Kenya</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Lesotho</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Liberia</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Madagascar</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Malawi</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Mali</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Mauritania</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Mauritius</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Mozambique</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Namibia</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Niger</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Nigeria</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Rwanda</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Sao Tome and Principe</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Senegal</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Seychelles</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>South Africa</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Swaziland</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Togo</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Uganda</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>United Republic of Tanzania</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Zambia</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>
## Appendixes

### PARTICIPANTS

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>47 Antigua and Barbuda</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>48 Argentina</td>
<td></td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>49 Bahamas</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 Barbados</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>51 Belize</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>52 Bolivia (Plurinational State of)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53 Brazil</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>54 Canada</td>
<td></td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55 Chile</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>56 Colombia</td>
<td></td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>57 Costa Rica</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>58 Cuba</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>59 Dominica</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 Dominican Republic</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>61 Ecuador</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>62 El Salvador</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>63 Grenada</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>64 Guatemala</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65 Guyana</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>66 Haiti</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>67 Honduras</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>68 Jamaica</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>69 Mexico</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70 Nicaragua</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>71 Panama</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>72 Paraguay</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>73 Peru</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>74 Puerto Rico*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75 Saint Kitts and Nevis</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>76 Saint Lucia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>77 Saint Vincent and the Grenadines</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>78 Suriname</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>79 Trinidad and Tobago</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80 The United States, USA</td>
<td></td>
<td>0</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>81 Uruguay</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>82 Venezuela (Bolivarian Republic of)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The First WHO Global Forum on Medical Devices Context, outcomes and future actions

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>83 Afghanistan</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>84 Bahrain</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85 Djibouti</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>86 Egypt</td>
<td>X</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>87 Iran (Islamic Republic of)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>88 Iraq</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>89 Jordan</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>90 Kuwait</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91 Lebanon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>92 Libyan Arab Jamahiriya (the)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>93 Morocco</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>94 Oman</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95 Pakistan</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Palestinian Authority</td>
<td></td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>96 Qatar</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>97 Saudi Arabia</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>98 Somalia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99 Sudan</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>100 Syrian Arab Republic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>101 Tunisia</td>
<td></td>
<td>O</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>102 United Arab Emirates</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>103 Yemen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>-------------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>104 Albania</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>105 Andorra</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>106 Armenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>107 Austria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>108 Azerbaijan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>109 Belarus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>110 Belgium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>111 Bosnia and Herzegovina</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>112 Bulgaria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>113 Croatia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>114 Cyprus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>115 Czech Republic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>116 Denmark</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>117 Estonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>118 Finland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>119 France</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>120 Georgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>121 Germany</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>122 Greece</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>123 Hungary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>124 Iceland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>125 Ireland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>126 Israel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>127 Italy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>128 Kazakhstan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>129 Kyrgyzstan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>130 Latvia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>131 Lithuania</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>132 Luxembourg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>133 The former Yugoslav Republic of Macedonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>134 Malta</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>135 Monaco</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>136 Montenegro</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>137 Netherlands</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>138 Norway</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>139 Poland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>140 Portugal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>141 Republic of Moldova</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>142 Romania</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>143 Russian Federation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>144 San Marino</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>145 Serbia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>146 Slovakia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>147 Slovenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>148 Spain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>149 Sweden</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>150 Switzerland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>151 Tajikistan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>152 The United Kingdom</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>153 Turkey</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>154 Turkmenistan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>155 Ukraine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>156 Uzbekistan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------------</td>
<td>-------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>SOUTH-EAST ASIA REGION</td>
<td>Bangladesh</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>157 Bangladesh</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>158 Bhutan</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>159 Cook Islands</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>160 Democratic People’s Republic of Korea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>161 India</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>162 Indonesia</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>163 Maldives</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>164 Myanmar</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>165 Nepal</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>166 Niue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>167 Sri Lanka</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>168 Thailand</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>169 Timor-Leste</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WESTERN PACIFIC REGION</td>
<td>Australia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>170 Australia</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>171 Brunei Darussalam</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>172 Cambodia</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>173 China</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>174 Fiji</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>175 Japan</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>176 Kiribati</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>177 Lao People’s Democratic Republic</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>178 Malaysia</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>179 Marshall Islands</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180 Micronesia (Federated States of)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>181 Mongolia</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>182 Nauru</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>183 New Zealand</td>
<td>O</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>184 Palau</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>185 Papua New Guinea</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>186 Philippines</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>187 Republic of Korea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>188 Samoa</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>189 Singapore</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>190 Solomon Islands</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>191 Tokelau*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>192 Tonga</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>193 Tuvalu</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>194 Vanuatu</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>195 Viet Nam</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

X — Includes government representation  
O — Observer or general participant representation  
* — Associate members
Appendix D

Organizing committees for the First WHO Global Forum on Medical Devices

Steering committee
Chair, Secretariat
Carissa Etienne, Assistant Director-General, Health Systems and Services
Steffen Groth, Director, Essential Health Technologies
Adriana Velazquez Berumen, Coordinator Diagnostic Imaging and Medical Devices Unit
World Health Organization

Members
Jennifer Barragan, World Health Organization
Deirdre Dimancesco, World Health Organization
Yadin David, International Federation for Medical and Biological Engineering (IFMBE)
Björn Fahlgren, World Health Organization
Josee Hansen, Ministry of Health, Welfare and Sport, the Netherlands
Peter Leeflang, Ministry of Health, Welfare and Sport, the Netherlands
Guy Maddern, International Network of Agencies for Health Technology Assessment (INAHTA)
Laura Sampietro-Colom, Health Technology Assessment International (HTAi);
Yot Teerawattananon, Ministry of Public Health Thailand
Sripen Tantivess, Ministry of Public Health Thailand
Bart Wijnberg, Ministry of Health, Welfare and Sport, the Netherlands

International organizing committee
Salma Abbasi, E-Worldwide Group
Barry Allen, International Union of Physical and Engineering Sciences in Medicine (IUPESM)
David Banta, Consultant
Simao Campos, International Standards Organization (ISO)
Monique Dory, Medicines Sans Frontieres (MSF)
Kalipso Chalkidou, National Institute of Public Health and Clinical Excellence (NICE)
Martha Emma Escandon, National Centre for Health Technology Excellence (CENETEC)
James Fitzgerald, Pan-American Health Organization (PAHO/WHO)
Charles A. Gardner, Forum for Health Research
Timothy Hancox, International Standards Organization (ISO)
Myriam Henkens
Kendall Ho, University of British Columbia
Sabina Hoeksta-van den Bosch, Ministry of Health, Welfare and Sport, the Netherlands
Adham Ismail, Eastern Mediterranean Regional Office, WHO
Jennifer Jackson, American College of Clinical Engineering
Ed Kelly, Patient Safety, WHO
Chapal Khasnabis, Assistive Devices, WHO
Paul LaBarre, PATH
Blerta Maliqui, Making Pregnancy Safer, WHO
Joseph Lazar Mathew, Health Technology Assessment International
Geeta Mehta, South East Regional Office, WHO
Iyad Mobarek, Jordan Country Office, WHO
David Porter, Consultant
Sarah Russell, Health System and Services, WHO
Roger Schmitt, HDS, WHO
Peter Smith, International Organization of Medical Physics
Ludo Scheerlinck, UNICEF
Herbert Voigt, International Federation for Medical and Biological Engineering
David Watson, ECRI Institute
Jomkwan Yothasamut, HITAP, Ministry of Health, Thailand

Local Organizing Committee
Chair Suwit Wibulpolprasert
Office of the Permanent Secretary, Ministry of Public Health

Members
Biomedical Instrument Division, Siriraj Hospital
Bureau of International Health, Ministry of Public Health
Bureau of Policy and strategy, Ministry of Public Health
Department of Medical Sciences, Ministry of Public Health
Department of Medical Services, Ministry of Public Health
Food and Drug Administration, Ministry of Public Health
Foundation for Consumers
Health Consumer Protection Project, Chulalongkorn University
Health Intervention and Technology Assessment Program, Ministry of Public Health
Health System Research Institute
Medical Device Control, Food and Drug Administration, Ministry of Public Health
National Health Security Office
National Health Commission Office
National Science and Technology Development Agency
Thai Health-Global Link Initiative Project, Mahidol University
The International Health Policy Program, Ministry of Public Health
The Medical Council of Thailand
Thai Medical Device Technology Industry Association
Social Security Office
World Health Organization Thailand
## Appendix E

### Programme of the First WHO Global Forum on Medical Devices

**Programme at a glance—9-11 September 2010**

**ATHENEE CRYSTAL BALLROOM**

<table>
<thead>
<tr>
<th>Day 1—Thursday 9 September</th>
<th>Day 2—Friday 10 September</th>
<th>Day 3—Saturday 11 September</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Check-in</strong></td>
<td><strong>Future trends in medical devices of relevance to low resource settings</strong></td>
<td><strong>Improving access, quality, and affordability of medical devices through...</strong></td>
</tr>
<tr>
<td><strong>Inauguration session</strong></td>
<td><strong>Space medical technology innovation and its global applications</strong></td>
<td><strong>Academia</strong></td>
</tr>
<tr>
<td><strong>08:30</strong> Mr Abhisit Vejjajiva, Prime Minister of the Kingdom of Thailand</td>
<td><strong>The future of health technology</strong></td>
<td><strong>Professional organizations</strong></td>
</tr>
<tr>
<td><strong>08:50</strong> Dr Margaret Chan, Director-General, WHO</td>
<td><strong>Q&amp;A</strong></td>
<td><strong>Technology transfer</strong></td>
</tr>
<tr>
<td><strong>09:00</strong> (French &amp; Spanish interpretation)</td>
<td><strong>French &amp; Spanish interpretation</strong></td>
<td><strong>Medical technology industry</strong></td>
</tr>
<tr>
<td><strong>09:10</strong></td>
<td><strong>Global status on medical devices</strong></td>
<td><strong>Q&amp;A</strong></td>
</tr>
<tr>
<td><strong>09:15</strong></td>
<td><strong>Prioritization, selection, and harmonization</strong></td>
<td><strong>French &amp; Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>09:20</strong></td>
<td><strong>Situation of global analysis of medical devices</strong></td>
<td><strong>Ethical practice</strong></td>
</tr>
<tr>
<td><strong>09:30</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>French &amp; Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>09:45</strong></td>
<td><strong>Local Solutions</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>10:00</strong></td>
<td><strong>Assessment and management: a continuous process</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>10:15</strong></td>
<td><strong>Preclinical and clinical evaluation</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>10:30</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>10:45</strong></td>
<td><strong>Appropriate technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>11:00</strong></td>
<td><strong>Global health innovations</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>11:15</strong></td>
<td><strong>Local Solutions</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>11:30</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>11:45</strong></td>
<td><strong>Appropriate and innovative medical technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>12:00</strong></td>
<td><strong>Meeting the needs of regulation and emerging technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>12:15</strong></td>
<td><strong>The need for continuous HTA in developing countries</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>12:30</strong></td>
<td><strong>The role of medical devices to improve health service delivery</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>14:00</strong></td>
<td><strong>Ethical practice</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>14:15</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>14:30</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>14:45</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>15:00</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>15:15</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>15:30</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>15:45</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>16:00</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>16:15</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>16:30</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>16:45</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>17:00</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>17:15</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>17:30</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>19:30</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>20:00</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
<tr>
<td><strong>20:30</strong></td>
<td><strong>In search of appropriate and innovative technologies</strong></td>
<td><strong>Spanish interpretation</strong></td>
</tr>
</tbody>
</table>

### Technical workshops in English (registration required)

- **Track 1:** Health Technology Assessment Room A (French interpretation)
- **Track 2:** Medical Devices Management Room B (Spanish interpretation)
- **Track 3:** Medical Devices Regulation Room C
- **Track 4:** e-Health Room D

### Post-conference workshops & meetings

- **Meeting of the Global Medical Technology Alliance**

---

41
### Programme day 1—Thursday, 9 September 2010

**ATHENEÉ CRYSTAL BALL ROOM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–08:30</td>
<td>Check-in</td>
</tr>
<tr>
<td>08:30–08:50</td>
<td>Inauguration session [French &amp; Spanish interpretation]</td>
</tr>
<tr>
<td></td>
<td>Welcome address</td>
</tr>
<tr>
<td></td>
<td>Mr Abhisit Vejjajiva, Prime Minister of the Kingdom of Thailand</td>
</tr>
<tr>
<td>08:50–09:10</td>
<td>Inauguration address [French &amp; Spanish interpretation]</td>
</tr>
<tr>
<td></td>
<td>Dr Margaret Chan, Director-General, WHO</td>
</tr>
<tr>
<td>09:20–10:30</td>
<td>Global status on medical devices</td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Carissa Etienne, WHO</td>
</tr>
<tr>
<td></td>
<td>Film</td>
</tr>
<tr>
<td></td>
<td>Situational global analysis of medical devices</td>
</tr>
<tr>
<td></td>
<td>Dr Steffen Groth, WHO</td>
</tr>
<tr>
<td></td>
<td>Mismatches in medical devices</td>
</tr>
<tr>
<td></td>
<td>Mrs Josee Hansen, Ministry of Health, Welfare, and Sport, Netherlands</td>
</tr>
<tr>
<td></td>
<td>Medical device needs in a developing country</td>
</tr>
<tr>
<td></td>
<td>Dr Pasieena Kibatalo, Saint Francis Designated District Hospital, Ifakara, Tanzania</td>
</tr>
<tr>
<td>10:30–11:15</td>
<td>Coffee break and poster session A</td>
</tr>
<tr>
<td>11:15–12:15</td>
<td>Medical devices and universal access [French &amp; Spanish interpretation]</td>
</tr>
<tr>
<td></td>
<td>Chair: Mr Bart Wijnberg</td>
</tr>
<tr>
<td></td>
<td>Co-Chair: Dr Evita Mehta</td>
</tr>
<tr>
<td></td>
<td>Keynote addresses:</td>
</tr>
<tr>
<td></td>
<td>Health systems strengthening and financing medical devices: suggestions for change</td>
</tr>
<tr>
<td></td>
<td>Dr Charles Ok Pamenborg, The World Bank</td>
</tr>
<tr>
<td></td>
<td>Empowering decision makers</td>
</tr>
<tr>
<td></td>
<td>Mr Andrew Dillon, National Institute for Health and Clinical Excellence</td>
</tr>
<tr>
<td>12:15–13:45</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:45–15:15</td>
<td>The role of medical devices to improve health service delivery [French interpretation]</td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Joseph Mathew</td>
</tr>
<tr>
<td></td>
<td>Co-Chair: Dr Nicholas Adiabu</td>
</tr>
<tr>
<td></td>
<td>MDGs and the role of medical devices: Dr Helene Molier, UNICEF</td>
</tr>
<tr>
<td></td>
<td>Clinical Programme Guidelines, Dr. Maki Esther Ortiz-Dominguez, Ministry of Health, Mexico</td>
</tr>
<tr>
<td></td>
<td>Self care: Dr Wim Van Opdenbosch, WHO, Mongolia</td>
</tr>
<tr>
<td>15:15–16:00</td>
<td>Coffee break and poster session A (continued)</td>
</tr>
<tr>
<td>16:00–17:30</td>
<td>Safe, affordable and affordable medical devices [French interpretation]</td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Peter Smith</td>
</tr>
<tr>
<td></td>
<td>Co-Chair: Dr Pablo Jiménez</td>
</tr>
<tr>
<td></td>
<td>Radiation safety: Dr Cordaidi Borrás, Universidad Federal de Pernambuco, Brazil</td>
</tr>
<tr>
<td></td>
<td>Access to radiotherapy: Mr Greene Morgan, Dr Joanna Lewiska, International Atomic Energy Agency</td>
</tr>
<tr>
<td></td>
<td>Palliative care and medical devices: Dr Barry Allen, International Union for Physical and Engineering Sciences in Medicine</td>
</tr>
<tr>
<td>19:30–22:00</td>
<td>Reception and dinner at the venue</td>
</tr>
</tbody>
</table>

The First WHO Global Forum on Medical Devices Context, outcomes and future actions
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
<th>Co-Chair</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–09:15</td>
<td>Future trends in medical devices of relevance to low resource settings</td>
<td>Ministry of Health, TBD</td>
<td>Mr. Jennifer Barragan</td>
<td>Dr Chiaki Mukai, Astronaut, JAXA Space Biomedical Research Office</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The future of health technology</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ms Renata Bushino, Future of Health Technology Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>09:15–10:30</td>
<td>In search of appropriate and innovative technologies</td>
<td>Ministry of Health, TBD</td>
<td>Dr Iyad Mobarek</td>
<td>Prof Dr Oluyembo Awojobi, Awojobi Clinic Eruwa, Nigeria</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dr Kristian Olson, Center for Integration of Medicine and Innovative Technology, Massachusetts General Hospital, Harvard University, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Appropriate technologies</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mr Paul LeBarre, PATH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Global health innovations</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dr Peter A Singer, McLaughlin-Rotman Centre for Global Health &amp; Grand Challenges Canada</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>10:30–11:15</td>
<td>Coffee break and poster session B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15–12:15</td>
<td>Strategies to promote safe, affordable, quality medical device use</td>
<td>Ministry of Health, TBD</td>
<td>Mr Pablo Jiménez</td>
<td>Dr Laura Sampietro-Colom, Health Technology Assessment International</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Regulation of medical devices</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dr. Ruth Lapert, Therapeutic Goods Administration, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medical devices management</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dr David Porter, United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>12:15–13:45</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45–14:45</td>
<td>Health technology assessment, regulation, and management of medical devices when evaluating the needs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Track 1 (HTA): Assessment for innovative and emerging technologies</td>
<td>Dr Pwee Keng Ho</td>
<td>Dr Iyad Mobarek</td>
<td>Dr Brendon Kearney, EuroScan</td>
</tr>
<tr>
<td></td>
<td>Track 2 (HTM): Pre-market approval including</td>
<td>Dr Daniel Tam</td>
<td>Dr Bjorn Fahlgren</td>
<td>Dr Marydee Patanawong, Food and Drug Administration, Thailand</td>
</tr>
<tr>
<td></td>
<td>prioritization procedures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Track 3 (HTM): Needs assessment: epidemiological</td>
<td>Mr Ronald Bauer</td>
<td>Mr Paul Rogers</td>
<td>Mrs Maria Luisa Gonzalez Rett, CENETEC, Ministry of Health, Mexico</td>
</tr>
<tr>
<td></td>
<td>need, inventory, and medical device lists</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45–15:45</td>
<td>Health technology assessment, regulation, and management of medical devices when evaluating the needs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Track 1 (HTR): HTA of medical devices: national</td>
<td>Dr Berit Morland</td>
<td>Dr Hayde Reynolds</td>
<td>Dr Djeppe Chaffikidou, National Institute for Health and Clinical Excellence</td>
</tr>
<tr>
<td></td>
<td>prioritization processes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Track 2 (HTR): Harmonization of regulation —</td>
<td>Mr Albert Poan</td>
<td>Mr Noboru Takamura</td>
<td>Dr Larry Kelly, Therapeutic Goods Administration, Australia</td>
</tr>
<tr>
<td></td>
<td>challenges and benefits</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45–16:30</td>
<td>Coffee break and poster session B (continued)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30–17:30</td>
<td>Assessment and management: a continuous process</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Programme day 3—Saturday, 11 September 2010
ATHENE CRYSTAL BALLROOM

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–10:05</td>
<td>Improving access, quality, and affordability of medical devices through… [French &amp; Spanish interpretation]</td>
</tr>
<tr>
<td></td>
<td>Chair: Ministry of Health, TBD</td>
</tr>
<tr>
<td></td>
<td>Co-Chair: Dr Adham Ismail</td>
</tr>
<tr>
<td></td>
<td>Academia</td>
</tr>
<tr>
<td></td>
<td>Dr Herbert Voigt, International Federation for Medical and Biological Engineering</td>
</tr>
<tr>
<td></td>
<td>Professional organizations</td>
</tr>
<tr>
<td></td>
<td>Dr Peter H S Smith, International Organisation for Medical Physics</td>
</tr>
<tr>
<td></td>
<td>Technology transfer</td>
</tr>
<tr>
<td></td>
<td>Dr Rosanna Peeling, London School of Hygiene &amp; Tropical Medicine, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Medical technology industry</td>
</tr>
<tr>
<td></td>
<td>Ms Anne Trimmer, Global Medical Technology Alliance</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>10:05–10:30</td>
<td>Ethical practice [French &amp; Spanish interpretation]</td>
</tr>
<tr>
<td></td>
<td>Mr Alexander Capron, University of Southern California</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>10:15–11:00</td>
<td>Rapporteur working session</td>
</tr>
<tr>
<td>10:30–11:15</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11:15–12:00</td>
<td>Closing session [French &amp; Spanish interpretation]</td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Steffen Groth, WHO</td>
</tr>
<tr>
<td></td>
<td>Day 1—Dr Geeta Mehta, SEARO, WHO</td>
</tr>
<tr>
<td></td>
<td>Day 2—Mr Pablo Jiménez, PAHO, WHO</td>
</tr>
<tr>
<td></td>
<td>Day 3—Mr Adham Ismail, EMRO, WHO</td>
</tr>
<tr>
<td>12:00–12:15</td>
<td>Way forward</td>
</tr>
<tr>
<td></td>
<td>Dr Carissa Etienne, WHO</td>
</tr>
<tr>
<td>12:15–12:30</td>
<td>Closing message</td>
</tr>
<tr>
<td></td>
<td>Dr Suwit Wibulpolprasert, Ministry of Health, Thailand</td>
</tr>
<tr>
<td>12:30–14:00</td>
<td>Closing lunch</td>
</tr>
</tbody>
</table>

POST CONFERENCE WORKSHOPS & MEETINGS

<table>
<thead>
<tr>
<th>Time</th>
<th>Technical workshops in English (registration required)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00–16:00</td>
<td>Track 1. Health Technology Assessment Room A</td>
</tr>
<tr>
<td></td>
<td>Track 2. Medical Devices Management Room B</td>
</tr>
<tr>
<td></td>
<td>Track 3. Medical Devices Regulation Room C</td>
</tr>
<tr>
<td></td>
<td>Track 4. e-Health Room D</td>
</tr>
<tr>
<td>16:00–17:00</td>
<td>Meeting of the Global Medical Technology Alliance, Room A</td>
</tr>
</tbody>
</table>
Appendix F
List of participants of the First WHO Global Forum on Medical Devices

AFRICAN REGION

ANGOLA
Dr Carlos MASSECA
Vice Ministro
Ministério da Saúde
Luanda

Ms Juliana FERREIRA
Direcção Nacional de Medicamentos e Equipamentos
Ministério da Saúde
Luanda

Mr Jai ESTEVAO
Ministerio da Saude
Luanda

Mr Manuel LACO
Informatica
Ministerio da Saude
Luanda

Mr Afonso WETE
Ministerio da Saude
Luanda

BENIN
Mrs Maliki Seidou ADJARATOU
Direction des Infrastructures, des Equipements et de la Maintenance du Ministère de la Santé
Ministère de la Santé Du Bénin
05 BP 1543
Cotonou 229

BOTSWANA
Ms Bonang Sylvia TIHOMELANG
Clinical Services
Ministry of Health
Box 54, Moshupa
Gaborone

BURKINA FASO
Dr Tiendrebeogo SYLVESTRE
Director of Disease Control
Ministry of Health
07 BP 5153
 Ouagadougou

BURUNDI
Mr Donatien NINONKURU
Departement de la Pharmacie, du Medicament et des Laboratoires
Ministère de la Santé Publique
Bp 1820
Bujumbura

CAMEROON
Dr Arthur Georges Alfred ESSOMBA
Ministry of Public Health
Yaounde 237

COMOROS
Dr Sounhadj ATTOUMANE
Hon. Minister of Health
Ministry of Health, Solidarity and Gender Promotion
P.O. Box 1028
Moroni

CONGO
Dr Esther Nina NGOYI
Health Ministry
Box 32
Brazzaville

COTE D’IVOIRE
Mr Kouame KOUKOU
Ministry of Health
22 BP 767
Abidjan 22

DEMOCRATIC REPUBLIC OF THE CONGO
Mr Johnny Malaba KALONJI
Ministry of Health
P.O.Box 1519
Kinshasa

EQUATORIAL GUINEA
Dr Pedro ABABO ESONO
Ministerio de Sanidad
Malabo

ERITREA
Mr Kubrom OGBAMICHAEL
Regulatory Services
Ministry of Health
P.O. Box 212
Asmara

ETHIOPIA
Mr Getachew DEBELA
Public Health Infrastructure Directorate
Federal Ministry of Health
Addis Ababa

GAMBIA
Mr Andrew DEMBA
Central Medical Stores
National Public Health Laboratories, Ministry of Health and Social Welfare
Biomedical Engineering Unit
Bertil Herding High Way, Kotu Layout
Banjul

GHANA
Mr John ZIENAA
Ghana Health Service
PMB Ministry
Accra

Mr Kwasi ADDAI-DONKOH
Ghana Health Service
PMB Ministry
Accra

GUINEA
Mr Abdoulaye FOFANA
Secretariat d’Etat a la Coopération Internationale Publique
Ministry of Health
Commune De Kaloum
Conakry 1210
### GUINEA-BISSAU
Mr. Hideraldu Antonio PIRES
Ministry of Health
Cupelad Cima-43
Bissau

### KENYA
Dr. Francis KIMANI
Ministry of Medical Services
30016
Nairobi 100

### MADAGASCAR
Dr. Pascal Jacques RAJAONARISON
Hon. Minister of Health
Ministère de la Santé
Gouvernement Malagasy
B.P. 88
Antananarivo 101

### MALI
Mr. Ogade MAIGA
Ministère de la Santé
B.P. 2650
Bamako

### MOZAMBIQUE
Dr. Armindo TONELA
Ministry of Health
Eduardo Mondlane Avenue 1008
Maputo

### NAMIBIA
Dr. Paulina NGHIPANDULWA
Ministry of Health And Social Services
Tertiary Health Care and Clinical Support Services
Private Bag 13198
Windhoek 9000

### NIGER
Dr. Saidaou MALLAM EKOYE
Secretariat Generale
Ministère de la Santé Publique
B.P. 623
Niamey

Mr. Abdou MAMAN
Direction des Infrastructures de Equipement Sanitaires
Ministère de la Santé Publique
B.P. 623
Niamey

Dr. Mariama Oumarou SAMBO
Ministère de la Santé Publique
B.P. 623
Niamey

### SAO TOME AND PRINCIPE
Mr. Florentino FERNANDES DOS RAMOS
Ministère de la Santé
Hopital Dr Ayres de Menezes
Sao Tome 109

### SENEGAL
Mr. Amad DIOUF
Direction des Equipements et de la Maintenance
Ministère de la Santé et de la Prévention
4024
Dakar

### SEYCHELLES
Dr. Joseph Joachim BISTOQUET
Radiology
Ministry of Health
P.O. Box 52
Victoria Mahe

### SIERRA LEONE
Mr. Joseph Bockarie MOIWO
Biomedical Engineering Unit
Directorate of Drugs and Medical Supplies
Central Medical Stores, New England Ville
Freetown

### SOUTH AFRICA
Mrs. Nonkondo MOLAI
National Department of Health
Ministry of Health
Private Bag X 828
Pretoria

### SWAZILAND
Dr. Samuel Vusi Victor MAGAGULA
Directorate of Health
Ministry of Health
P.O. Box 3163
Mbabane H100

### TOGO
Mr. Komlan EDOH-KOSSI
Maintenance Hospitalière et Biomédicale
Ministère de la Santé Direction des Affaires Communes (Dac) Lomé Togo
B.P. 336
Lomé

### UGANDA
Mr. James Kakoza MUTAGUBYA
Ministry of Health
P.O. Box 7272
Kampala

Mr. Sam WANDA
Health Infrastructure Division, Clinical Services Department
Ministry of Health
P.O. Box 7272
Kampala

### UNITED REPUBLIC OF TANZANIA
Mr. Joseph Philemon MGAYA
Directorate of Director General
Medical Stores Department
P.O. Box 9081, Off Nyerere Road
Dar Es Salaam 255

Dr. Pascience KIBATALA
Ministry of Health
P.O. Box 73
Ifakara 73

Mr. Hiiti Baran SILLO
Tanzania Food and Drugs Authority
P.O. Box 77150
Dar Es Salaam

### ZAMBIA
Mr. Tsibu BBUKU
Clinical Care and Diagnostic Services
Ministry of Health
P.O. Box 50055, Ridgeway 15102
Lusaka

### ZIMBABWE
Dr. Christopher TAPFUMANEYI
Ministry of Health
Po Box CY 1122 Causeway
Harare
PAN AMERICAN REGION

BELIZE
Mr Adrian CARDINEZ
Ministry of Health
National Engineering and Maintenance Center
Lottie Waight Street, Khnh Compound
Belize City

BRAZIL
Mr José Carlos DA SILVA MOUTINHO
National Health Surveillance Agency - Anvisa
S. I. A., Trecho 5, Área Especial 57
Brasília -Distrito Federal 71205-050
Dr Roberto Eduardo HESS DE SOUZA
Secretary of State for Health of Santa Catarina
Rua Esteves Junio, 160
Florianopolis-Santa Catarina 88015130
Dr Luiz Felipe NOBRE
Santa Catarina State Health Secretary
Rua Esteves Junior,390,7º Andar, Centro
Florianópolis 88015130
Mr Vinicius PAWLOWSKI QUEIROZ
Agencia Nacional De Vigilância Sanitária
Brasília -Distrito Federal 71205-050

CHILE
Mrs Ana Maria CONCHA
Instituto de Salud Publica de Chile / Public Health Institute of Chile
National Control Department - Medical Devices Office
Avenida Marathon N° 1000, Nunoo
Santiago 7780050

COSTA RICA
Dr María Del Carmen OCONTRILLO
Departamento de Tecnovigilancia en Salud
Ministerio de Salud
Distrito Hospital
Calle 16, Ave. 6 y 8
San José 10123-1000

CUBA
Dr Dulce Maria MARTINEZ PEREIRA
Centro de Control Estatal de Equipos Medicos
Ministerio de Salud Publica
Calle 4 Numero 455 Entre19 y 21 Vedado
Municipio Plaza de La Revolucion
La Habana 10400

JAMAICA
Mr Garfield PRESCOD
Ministry of Health

MEXICO
Dr Maki Esther ORTIZ-DOMINGUEZ
Ministry of Health
Integration and Development Viceministry
Lijae No. 7, Col. Juarez, Deleg. Cuahtemoc
Mexico D.F. 6600

Mrs Maria Luisa GONZALEZ-RETIZ
CENETEC / Ministry of Health
Reformas No. 450, Piso 13 Colonia Juarez
Mexico D.F. 6600

Ms Marcela Angelica VAZQUEZ CORONADO
Ministry of Health
Mobile Medical Units National Coordinator
Mexico D.F. 6600

PARAGUAY
Dr Edgar GIMENEZ CABALLERO
Vice-Minister of Health
Ministerio de Salud Publica y Bienestar Social
Fulgencio R. Moreno y Brasil
Asuncion

SURINAME
Mrs Sonja GALIMO
Ministry of Health
International Relations
H.A.E. Aronstraat 64
Paramaribo

TRINIDAD AND TOBAGO
Dr Ronald KOYASS
Ministry of Health
Academic Hospital Paramaribo
Paramaribo

UNITED STATES OF AMERICA
Ms Erin KEITH
Food And Drug Administration, Office of International Programs,
India Office
9000 New Delhi Pl
Dulles 20189-9000

Mr Richard PADDOCK
U.S. Department of Commerce
International Trade Administration
14th & Constitution Ave. NW
Washington, D.C. 20230

Mr Nalin PHUPOKSAKUL
U.S. Department of Commerce
U.S. Commercial Service, American Embassy
93/1 Wireless Road, Pathumwan
Bangkok 10330

Ms Marcela Angelica VAZQUEZ CORONADO
Ministry of Health
Mobile Medical Units National Coordinator
Mexico D.F. 6600

EASTERN MEDITERRANEAN REGION

AFGHANISTAN
Dr Sayed Kabir AMIRI
Hospital Management
Ministry of Health
The Great Masoud Road
Kabul

BAHRAIN
Mr Mahmood Jawad AL AAU
Medical Equipment Department
Ministry of Health
P.O. Box 12
Manama

DJIBOUTI
Dr Sillaye Abdallah ALI
Ministry of Health Djibouti
B.P. 4130
Djibouti
EUROPEAN REGION

ALBANIA
Mrs Ledina PICARI
Ministry of Health
Bul “Bajram Curri”
Tirana

ARMENIA
Mr Albert SAHAKYAN
Scientific Center of Drug And Medical Technology Expertise
Ministry of Health
15/1 Moskovyan Str
Yerevan

AZERBAIJAN
Mr Ramiz KERIMOV
Innovation and Supply Centre
3 Haji Hasan Road, Hujasan Village
Baku AZ100

CROATIA
Dr Dubravko BAJRAMOVIC
Department for National Waiting Lists, Directorate of Medical Affairs
Ministry of Health and Social Welfare
Ksaver 200A
Zagreb 10000

DENMARK
Mrs Ellen JESPERSEN
Consumer Safety Division, Medical Devices
Danish Medicines Agency
Axel Heides Gade 1
Copenhagen 2300

ESTONIA
Mr Tairi VÄLINURM
Medicine Department
Ministry of Social Affairs
Gonsiori 29
Tallinn 15027

GEORGIA
Mrs Eka PAATASHVILI
Healthcare Department
Ministry of Labour, Health and Social Affairs
144 Tsereteli Ave.
Tbilisi 119

ITALY
Dr Giuseppe RUOCCO
Dept. of Medicines and Medical Devices
Ministry of Health
Via Ribotta, 5
Roma 144

KYRGYZSTAN
Mrs Abalieva AINURA
Department of Drug Provision and Medical Equipment
Ministry of Health
25 Tretiya Liniya
Bishkek

NETHERLANDS
Mrs Josephina HANSEN
Ministry of Health, Welfare and Sport
Postbus 90460
The Hague 2509 LL

Ms Sabina HOEKSTRA-VAN DEN BOSCH
Pharmaceutical Affairs and Medical Technology
Ministry of Health, Welfare and Sport
Pb Box 20350
The Hague 2500EJ
Appendices

Mr Hugo HURTS
Ministry of Health, Welfare and Sport
Po Box 20350
The Hague 2500EJ

Mr Tjaco VAN DEN HOUT
The Hague

Mr Bart WUNBERG
Department of Pharmaceuticals and Medical Technology
Ministry of Health, Welfare And Sport
P.O. Box 20350
The Hague 2500 EJ

POLAND
Dr Marek TWARDOWSKI
Ministry of Health
15 Miodowa Str.
Warsaw 00-952

Mrs Joanna KILKOWSKA
Medical Devices Department
The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Zabkowska 41
Warsaw 03-736

Mr Sebastian MIGDALSKI
Drug Policy and Pharmacy Department
Ministry of Health
15 Miodowa Str.
Warsaw 00-952

Mr Mateusz MADRY
Ministry of Health
15 Miodowa Str.
Warsaw 00-952

PORTUGAL
Dr Mariana Isabel VAZ AFONSO PIRES MADUREIRA
Directorate Health Products
Infarmed – National Authority of Medicines and Health Products, I.P.
Parque de Saúde de Lisboa - Avenida do Brasil, 53
Lisbon 1749-004

Mrs Maria Judite VILELA GUERLIXA FIRMINO DAS NEVES
Directorate Health Products
Infarmed – National Authority of Medicines and Health Products, I.P.
Parque de Saúde de Lisboa - Avenida do Brasil, 53
Lisbon 1749-004

REPUBLIC OF MOLDOVA
Dr Vladimir HOTINEANU
Hon Minister of Health
Ministry of Health
2, V.Alecsandri Str.
Chisinau MD-2009

Dr Eugenia BERZAN
External Relations and European Integration Department
Ministry of Health
2, V.Alecsandri Str.
Chisinau MD-2009

REPUBLIC OF MONTENEGRO
Dr Erna SEHOVIC
Agency for Medicines and Medical Devices of Montenegro
II Crnogorski Bataljon Bb
Podgorica 81000

SPAIN
Dr Antonio SARRIA-SANTAMERA
Instituto de Salud Carlos III
Agencia de Evaluacion de Tecnologias Sanitarias
Monforte de Lemos 5
Madrid 28029

SWITZERLAND
Ms Dunia BRUNNER
Embassy of Switzerland in Bangkok
35 North Wireless Road
Bangkok 10330

TAJIKISTAN
Mr Sohibnazar RAHMONOV
Deputy Health Minister
Ministry of Health
69, Shevchenko Str
Dushanbe 734025

Dr Abdurashit MUROTOV
Ministry of Health
69, Shevchenko Str
Dushanbe 734025

UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
Andrew DILLON
Chief Executive
National Institute for Health and Clinical Excellence
Midcity Place, 71 High Holborn
London WC1V 6NA

Kalypso CHALKIDOU
National Institute for Health and Clinical Excellence
Midcity Place, 71 High Holborn
London WC1V 6NA

Dr David FORD
Healthcare & Testing Services
British Standards Institution
389 Chiswick High Road
London W4 4AL

TURKMENISTAN
Mr Bally BALLYEV
Production Unit “Medical Equipment”
2056/3 Viliams Str.
Ashgabat

UKRAINE
Dr Sergii DANYLOV
Department of Regulatory Policy
Ministry of Health Care
Grushevskogo Str. 7
Kiev

SOUTH-EAST ASIA REGION

BHUTAN
Dr Karma HAIZEN
Department of Medical Services
Ministry of Health
Thimphu

INDONESIA
Mrs Engko SOSIALINE MAGDALENE
Directorate General Pharmaceuticals and Medical Devices
Ministry of Health
Jl. Hr. Rasuna Said Blok X5 Kavling No. 4-9
Jakarta Selatan 12950

MALDIVES
Mrs Aishath MOHAMED
Maldives Food and Drug Authority (Mfd),
Soasun Magu
Male’ 200500

Mrs Aminath JAMEEL
Ministry of Health and Family
Ameenee Magu
Male’ 20086
NEPAL

Dr Mingmar SHERPA
Logistic Management Division
Ministry of Health And Population
GPO Box 1562
Kathmandu

THAILAND

His Excellency Mr Abhisit VEJJAJIVA
Prime Minister of the Kingdom of Thailand

Mr Jurin Lasanawisit
Hon Minister of Health

Dr Sumit WIBULPOLPRASERT
Ministry of Public Health
Tiwanon Road
Nonthaburi 11000

Ms Yuwadee PATANAWONG
Medical Device Control Division
Food and Drug Administration
Ministry of Public Health
Tiwanon Road
Nonthaburi 11000

Dr Yot TEERAWATTANANON
Health Intervention and Technology Assessment Program (HITAP)
Department of Health
Ministry of Public Health
Tiwanon Road
Nonthaburi 11000

Ms Chinda TONGRUANG
Department of Medical Sciences
Bureau of Radiation and Medical Devices
Ministry of Public Health
Tiwanon Road
Nonthaburi 11000

Ms Pasu SIRISALEE
National Metal and Materials Technology Center
114 Thailand Science Park
Phahonyothin Rd. Klong 1 Klong Luang
Pathumthani 12120

Ms Sathita SAKWISED
Department of Medical Sciences
Bureau of Radiation and Medical Devices
Ministry of Public Health
Tiwanon Road
Nonthaburi 11000

Mrs Varunee BORHIRUNRAT
Government Pharmaceutical Organization
75/1 Rama 6 Road, Ratchathewi
Bangkok 10400

Ms Siriphan EAMRUNGROJ
Food and Drug Administration
Ministry of Public Health
Tiwanon Road
Nonthaburi 11000

Mr Padet JANTAPALUEK
Medical Engineering Division
Ministry of Public Health
Tiwanon Road
Nonthaburi 11000

Dr Orasa KOWNDHA
Bureau of Policy and Strategy
Ministry of Public Health
Tiwanon Road
Nonthaburi 11000

Ms Danu PROMMIN
National Science and Technology Development Agency
114 Thailand Science Park
Phahonyothin Rd. Klong 1 Klong Luang
Pathumthani 12120

Mr Pongpan VONGMANEE
Food and Drug Administration
Ministry of Public Health
Tiwanon Road
Nonthaburi 11000

TIMOR-LESTE

Mr Horacio Fernandes RIBEIRO
Medical Devices
Ministry Of Health
Edifício dos Serviços Centrais do Ministério da Saúde
Rua de Caicoli, Caixa Postal 374
Dili

Mr Moises XIMENES
Medical Devices
Ministry of Health
Edifício dos Serviços Centrais do Ministério da Saúde
Rua de Caicoli, Caixa Postal 374
Dili

WESTERN PACIFIC REGION

AUSTRALIA

Dr Horvath JOHN
Commonwealth Government of Australia
GPO Box 9848
Sydney 2001

Dr Lawrence KELLY
Monitoring and Compliance Group
Therapeutic Goods Administration
Po Box 100
Woden Act 2606

Dr Ruth LOPERT
Therapeutic Goods Administration
136 Narrabundah Lane
Symonston 2609

BRUNEI DARUSSALAM

Mr Haji Zinal Abadin HAJI AHMAD
Healthcare Technology Department
Ministry of Health
Bandar Seri Begawan BB2710

Mr Abidin OTHMAN
Ministry of Health
Commonwealth Drive
Berakas BB3910

CAMBODIA

Dr Sivuthy CHEU
Hospital Services Department
Ministry of Health
#151-153, St. Kampuchea Krom
Phnom Penh

CHINA (THE PEOPLE’S REPUBLIC OF)

Mr Shun Yuen LAM
Medical Device Control Office
Department of Health
Room 3101, 31/F, Hopewell Centre
183 Queen’s Road East, Wan Chai
Hong Kong SAR
Dr Teresa Li
Department of Health
21/F, Wu Chung House
213 Queen’s Road East, Wan Chai
Hong Kong SAR

Mr Jun Li
Department of Planning and Finance
Ministry of Health
1 Xizhimenwai Nan Road
Beijing 100044

Dr Gloria Tam
Department of Health
Room 2118, Wu Chung House
213 Queen’s Road East, Wan Chai
Hong Kong SAR

Ms Pei-Weng Tu
Bureau of Food and Drug Administration
77, No. 80, Lin Sen N. Rd. Jhongshan
Taipei 10441

JAPAN
Mr Yamashita Mamoru
Embassy of Japan in Thailand
177 Withthayu Road Lumpini
Bangkok 10330
Thailand

Dr Masato Mugitani
Minister’s Secretariat
Ministry of Health, Labour and Welfare
1-2-2 Kasumigaseki, Chiyoda-Ku
Tokyo 100-8916

Dr Hidemori Yamamoto
International Affairs Division, Minister’s Secretariat
Ministry of Health, Labour and Welfare
1-2-2 Kasumigaseki, Chiyoda-Ku
Tokyo 100-8916

Mr Shinichi Mizumoto
Japan Aerospace Exploration Agency
B.B. Building Room 1502
54 Asoke Road, Wattana
Bangkok 10110
Thailand

Mr Takeshi Matsuo
Japan International Cooperation Agency (JICA)
c/o Jica Cambodia Office
P.O. Box 613
Phnom Penh
Cambodia

KIRIBATI
Dr Patrick Timeon
Ministry of Health & Medical Services
Bikenibeu, Tarawa

LAO PEOPLE’S DEMOCRATIC REPUBLIC
Mr Thanom Insal
Ministry of Health
Fa-Ngum Road, Sittanack District
Vientiane Capital

MICRONESIA (FEDERATED STATES OF)
Mr Samo Marcus
Department of Health and Social Affairs
Ministry of Health
P.O. Box PS 70
Palikir 96941

MONGOLIA
Mrs Munkhdelger Chimedtseren
Division of Pharmaceuticals and Medical Devices
Ministry of Health
Olympic Street-2, Government Building-8
Ulaanbaatar

NAURU
Mr Tonela Sunia Soakai
Ministry of Health
Yaren District

Ms Christiana Denitage
Vice-Consul of The Nauru Consulate General Office
765/1 Pracha-Uthit Road
Samsennok, Huay Kwang
Bangkok 10320
Thailand

PHILIPPINES
Ms Agnette Peralta
Bureau of Health Devices and Technology
Department of Health
San Lazaro Compound
Rizal Avenue, Sta. Cruz
Manila 1003

SAMOA
Mrs Gatolaifaana Gizlow
Hon. Minister of Health
Ministry of Health
P.O. Box 2268
Apia

Mr Take Naseri
Ministry of Health
Private Bag, Moto’otua
Apia

SINGAPORE
Mr Alvin Gay
Ministry of Health
College of Medicine Building
16 College Road
Singapore 160078

Mrs Joanna Koh
Health Sciences Authority of Singapore
11 Biopolis Way, #11-01 Helios Bldg.
Singapore 138667

Dr Christina Lim
Health Sciences Authority of Singapore
11 Biopolis Way, #11-01 Helios Bldg.
Singapore 138667

Dr Keng Ho Pwee
Health Technology Assessment Branch
Ministry of Health
16 College Road
Singapore 160078

Dr Daniel Tan
Policy Legislation and Operations
Health Sciences Authority of Singapore
11 Biopolis Way, #11-01 Helios Bldg.
Singapore 138667

VANUATU
Dr Trelly Samuel Patunvanu
Norsup Hospital (Public Hospital)
Private Mail Bag 04
Norsup Central Malekula
Lakatoro 678
VIET NAM
Minh Tuan NGUYEN
Dept. of Medical Equipment and Health Facilities
Ministry of Health
138 A Giang Vo Ba Dinh Distr.
Hanoi

PROFESSIONALS
Dr Barry ALLEN
International Union for Physical and Engineering Sciences in Medicine (IUPESM)
5 Muneela Place
Yowie Bay 2228
Australia

Dr Arshad ALTAF
Vanderbilt Institute for Global Health
69-C, First Floor, Block-2, Pechs
Karachi 74500
Pakistan

Dr Oluyombo AWOJOBI
Awojobi Clinic Eruwa
P O Box 5
Eruwa 2000010
Nigeria

Mr Ronald BAUER
Saniplan Gmbh
Homburger Landstr. 838
Frankfurt Am Main 60437
Germany

Dr Upendra BISWAL
Post Graduate Institute of Medical Education & Research
Dr. R.M.L. Hospital
Baba Kharak Singh Marg
New Delhi 110001
India

Dr Caridad BORRAS
Department of Nuclear Energy, Dosimetry and Nuclear Instrumentation Group
Federal University of Pernambuco
Av. Prof. Luiz Freire, 1000
Recife, Pernambuco PE 50740-540
Brazil

Ms Renata BUSHKO
Future of Health Technology Institute
United States of America

Ms Raquel CABO
London School of Economics
Switzerland

Dr Saide Jorge CALIL
Department of Biomedical Engineering
Universidade de Campinas
Centro de Engenharia Biomedicarua Alexandre Fleming 181
Campinas 13083-881
Brazil

Mr Alexander Morgan CAPRON
University of Southern California
6900 Exposition Blvd
Los Angeles 90089-0071
United States of America

Dr Guillermo CARROLI
Centro Rosarino de Estudios Perinatales
Pueyrredon 985
Rosario 2000
Argentina

Ms Anjum CHAGPAR
Healthcare Human Factors
Centre for Global e-Health Innovation, University Health Network
190 Elizabeth St, 4th Floor, R. Fraser Elliot Building
Toronto M5G 2C4
Canada

Mr Nathorn CHAIYAKUNAPRUK
Center of Pharmaceutical Outcomes Research, Naresuan University Faculty of Pharmaceutical Sciences
Phitsanulok 65000
Thailand

Dr Jie CHEN
School of Public Health
Fudan University, School of Public Health
P.O.Box 197139
Yi Xue Yuan Road
Shanghai 200032
China

Mr John Tobey CLARK
Instrumentation & Technical Services/Biomedical Engineering
University of Vermont
280 East Avenue St
Burlington 05401
United States of America

Dr Patrick CUENOUD
Cabinet Médicalchemin de Pierrefleur 60
Lausanne 1004
Switzerland

Mrs Monique DORY
Médecins sans Frontières
94 Rue Dupre1090 Brusselsbelgium
Bruxelles 1090
Belgium

Ms Faye FERRER
Mercury in Health Care
Health Care Without Harm Southeast Asia
Unit 330 Eagle Court Condominium
26 Matalino Street, Brgy. Central Diliman
Quezon City 1100
Philippines

Dr Renato GARCIA OJEDA
IEB-Universidad Florianopolis Santa Catarina
Campus Universitario – Trindade Florianopolis
Caixa Postal 5138
Florianópolis 88040-970
Brazil
Appendices

Mr Jonathan GAEV  
ECRI Institute  
5200 Butler Pike  
Plymouth Meeting 19462-1298  
United States Of America

Mr Brian GOEMANS  
Medical Devices to Market  
Po Box 3372, Mowbray  
Cape Town 7925  
South Africa

Dr Christopher HENSHALL  
Health Technology Assessment International  
13 St Mary's Grove  
London  
United Kingdom of Great Britain And Northern Ireland

Dr Hideyuki HIROSE  
National Rehabilitation Center for Persons with Disabilities  
4-1, Namiki, Tokorozawa  
Salama 359-8555  
Japan

Dr Kendall HO  
Ehealth Strategy Office  
University of British Columbia Faculty of Medicine  
202-885 West 10th Avenue  
Vancouver, V5Z 1L7  
Canada

Dr Fred HOSEA  
Clinical Technology  
Kaiser Permanente  
1795 Second Street  
Berkeley, California 94710  
United States of America

Mrs Jennifer JACKSON  
Robotics and Movement Analysis Laboratory  
La Sapienza University & Bambino Gesu Hospital  
Viale Medaglie D'Oro, 159  
Rome 136  
Italy

Ms Robinah KAITIRITIMBA  
Uganda National Health Users/Consumers Org.  
P.O.Box 70095  
Kampala  
Uganda

Dr Churnrurtai KANCHANACHITRA  
Mahdol University  
999 Phuttamonthon 4 Road, Salaya  
Nakhon Pathom  
Thailand

Mr Aysheshm KASSAHUN  
Microbiology, Immunology and Parasitology  
Addis Ababa University, Medical Faculty  
P.O.Box 9086  
Addis Ababa  
Ethiopia

Dr Brendan KEARNEY  
EUROSCAN  
101 Watson Avenue, Toorak Gardens  
Adelaide 5065  
Australia

Mr Abdelbaset KHALAF  
Clinical Engineering  
Tshwane University of Technology  
P.O.Box 250  
Willow Acres Estate  
Pretoria 95  
South Africa

Dr Lawal KHALID  
Clinical Services, Training and Research  
Ahmadu Bello University Teaching Hospital  
PMB 006  
Zaria  
Nigeria

Dr Niranjani KHAMBETE  
Biomedical Technology Wing, Instrumentation Laboratory  
Sree Chitra Tirunal Institute for Medical Sciences and Technology  
Satelmond Palace Campus, Poojapura  
Thiruvananthapuram 695012  
India

Dr Bala KRISHNAN  
Aravind Eye Care System  
1 Sivajangai Main Road, Veerapanjan  
Madurai 629020  
India

Mr Paul LABARRE  
PATH  
PO Box 90922  
Seattle 98109  
United States of America

Mr Logan MARDHANI-BAYNE  
Health Technology Assessment International  
1200 10405 Jasper Avenue NW  
Edmonton  
Canada

Dr Joseph L. MATHEW  
Advanced Pediatrics Centre  
Postgraduate Institute of Medical Education and Research  
Chandigarh 160012  
India

Mrs Ruth MCNERNEY  
London School of Hygiene and Tropical Medicine  
United Kingdom of Great Britain And Northern Ireland

Ms Yvette MIRABAL  
Rice 360: Institute for Global Health Technologies  
Rice University  
6100 S. Main St -MS 636  
Houston 77005  
United States Of America

Mr Luciano MOCCIA  
East Meets West Foundation  
No. 1 Lane, 40 Linh Lang Street  
Ba Dinh District  
Hanoi  
Viet Nam

Dr Berit Sofie MØRLAND  
Norwegian Knowledge Centre for the Health Services  
PO Box 7004  
St.Olavs Plass  
Oslo N-0130  
Norway

Dr Chiaki MUKAI  
Japan Aerospace Exploration Agency (JAXA)  
2-1-1 Sengen  
Tsukuba, Ibaraki Prefecture 305-8505  
Japan

Ms Shauna MULLALLY  
Medical Research Council (UK) The Gambia  
Atlantic Blvd., Fajara  
P.O. Box 273  
Banjul  
Gambia
Mr Jeremiah MWANGI
International Alliance of Patients’ Organizations
Unit 703, The Chandlery
50 Westminster Bridge Road
London SE17QY
United Kingdom of Great Britain And Northern Ireland

Mr Ebrima NYASSI
Medical Research Council (UK) The Gambia
Atlantic Blvd., Fajara
P.O. Box 273
Banjul
Gambia

Dr Marc NYSSSEN
International Federation for Medical and Biological Engineering (IFMBE)
Laarbeeklaan 103
Brussels (Jette) 1090
Belgium

Dr Kristian OLSON
CIMIT Global Health Initiative
Harvard University, Massachusetts General Hospital
50 Staniford Street, Suite 503B
Boston 02114
United States Of America

Mr Rob PARSONS
Health Partners International
Unit F1, Waterside Centre, North St
Lewes, East Sussex BN7 2PE
United Kingdom Of Great Britain And Northern Ireland

Dr Rosanna PEELING
London School of Hygiene and Tropical Medicine
London WC1E 7HT
United Kingdom of Great Britain and Northern Ireland

Mr Mladen POLUTA
Biomedical Engineering Division, Dept. of Human Biology
University of Cape Town
Health Sciences Faculty
Anzio Road Observatory
Cape Town 7925
South Africa

Mr Albert Ka-Fat POON
Hong Kong SAR B52
China

Dr David PORTER
21 Stewarton Drive, Cambuslang
Glasgow G72 8DF
United Kingdom of Great Britain and Northern Ireland

Dr Carole PRESERN
Maternal and Child Health Advocacy International
83 Derby Road
Nottingham NG1 5BB
United Kingdom of Great Britain And Northern Ireland

Ms Lisa Anne SPELLMAN TRIMBLE
Healthcare and Information Management Systems Society
4677 Running Deer Woods NE 52240
United States Of America

Dr Laura SAMPietRO-COLOM
Health Technology Assessment International and Hospital Clinic Barcelona
C/ Villarroel 170
Barcelona 9036
Spain

Dr Javier Alfonso SCHWARTZMAN
Obstetricia y Ginecologia
Centro de Educacion Medica e Investigaciones Clinicas - CEMIC
Galvan 4102
Buenos Aires C1431FWD
Argentina

Mr Benjamin SCHANKER
Harvard Medical School
United States of America

Mrs Kathleen SIENKo
University of Michigan
2350 Hayward St.
2250 GG Brown Building
Ann Arbor 48109
United States of America

Dr Peter A. SINGER
Mclaughlin-Rotman Centre for Global Health
101 College Street, Suite 406
Toronto M5G 1L7
Canada

Dr Peter SMITH
International Organization for Medical Physics
86 Lisbane Road, Saintfield, Co. Down
Ballynahinch BT24 7BT
United Kingdom of Great Britain And Northern Ireland

Dr David SOUTHALL
Maternal and Child health Advocacy International
83 Derby Road
Nottingham NG1 5BB
United Kingdom of Great Britain And Northern Ireland

Dr Gerrit VAN ARK
Organization for Health R&D (ZONMW)
P.O. Box 93245
The Hague 2509 AE
Netherlands
WHO CALL FOR INNOVATIVE TECHNOLOGIES

Dr Sangeeta BHATTACHARYA
Indian Institute of Technology Kharagpur
School of Medical Science and Technology
West Bengal 721302
India

Ms Sarah BURGARELLA
ST Microelectronics, Advanced System Technology
Via C. Olivetti 2, Pal. Fiordaliso
Agrate Brianza (Mi) 20041
Italy

Mr Jens Petter IANKE
Laerdal Medical, Research and Development
P.O. Box 377
Stavanger 4002
Norway

Dr Herrmann KRANZL
Aquis GmbH, Research and Development
Marburger Strasse 86 c
Marburg 35043
Germany

Mr José Carlos LAPENNA
Diagnostek
Rua Padre Antonio Pacheco Da Silva, 431
Itu 13313-003
Brazil

Dr Anam MIDHA
Biosense Technologies Private Limited, Research & Development
304, Jaltarang, Lokpuram,Gladys Alvares Marg
Hiranandani Meadows
Thane 400610
India

Mr Jorge Ernesto ODÓN
San Martin 1884
Buenos Aires 1828
Argentina

Mr Rahul PANICKER
Embrace
No: 1332, 1st Floor, Janardhan Towers
Residency Road
Bangalore 560 025
India

Dr Yogesh PATIL
Biosense Technologies Private Limited
304, Jaltarang, Lokpuram, Gladys Alvares Marg
Thane 400610
India

Mr Mark SMITH
HSA Global Ltd
Level 2, 25 Broadway
PO Box 109462, Newmarket
Auckland 1149
New Zealand

Mrs Qimin YOU
Ustar Biotechnologies (Hangzhou) Ltd.
456 Wenyi Road, West, 4th Floor
Hangzhou 310012
China

Ms Anna YOUNG
Massachusetts Institute of Technology
Innovations in International Health
77 Massachusetts Ave., Building 4-110
Cambridge 02139
United States of America

MEDICAL DEVICE ASSOCIATIONS

Mr Philippe AUCLAIR
Regulatory Affairs
Medical Technology Association of New Zealand (MTANZ)
PO Box 74116
Greenlane Central
Auckland 1546
New Zealand

Dr Preecha BHANDTIVEJ
Thai Medical Device Industry Association
11th Fl., Dr. Gerhard Link Bldg.
88 Krungthepkreetha Rd., Huamark, Bangkapi
Bangkok 10240
Thailand

Ms Fernanda DE OLIVEIRA MACHADO
Advanced Medical Technology Association (ADVAMED) / Canada’s Medical Technology Companies (MEDEC)
701 Pennsylvania Ave, N.W., Suite 800
Washington, D.C. 20004-2654
United States of America

Mrs Renuka GADDE
Advanced Medical Technology Association (ADVAMED)
701 Pennsylvania Ave, N.W., Suite 800
Washington, D.C. 20004-2654
United States of America

Mr Michael GROPP
EUCOMED
Place des Maïeurs 2
Brussels 1150
Belgium

Mr Ralph IVES
Advanced Medical Technology Association (ADVAMED)
701 Pennsylvania Ave, N.W., Suite 800
Washington, D.C. 20004-2654
United States of America

Mr Robert KRAKOWIAK
Secretariat
Safety Injection Solutions Alliance (SISA)
Suite 2809, 500 Xiang Yang Road
Shanghai 200031
China
The First WHO Global Forum on Medical Devices Context, outcomes and future actions

Dr Mallika LATAVALYA NA AYUDHAYA
Thai Medical Device Technology Industry Association
11th Fl., Dr. Gerhard Link Bldg.
88 Kruengthepkreetha Rd., Huamark, Bangkapi
Bangkok 10240
Thailand

Mr Michael LIM
Canada’s Medical Technology Companies (MEDEC)
405 The West Mall, Suite 900
Toronto M9C 5J1
Canada

Ms Mary LOGAN
The Association for the Advancement of Medical Instrumentation (AAMI)
4301 N Fairfax Dr, Suite 301
Arlington 22203
United States of America

Mr Laurent METZ
Medical Technology Association of Australia (MTAA)
Level 12, 54 Miller Street
North Sydney NSW 2060
Australia

Mr Shigetaka MIURA
Japanese Federation of Medical Device Associations (JFMDA)
3-1-9, Nihonbashi Honcho, Chuo-Ku
Tokyo 103-0023
Japan

Mr Carlos MOTTA
Medical Devices Chamber
National Business Association of Colombia
Calle 73 # 8-13 Torre A Piso 7
Bogota
Colombia

Mr Masaaki NAITO
Japan Federation of Medical Devices Associations
8F B, Ibadashi Square Bldg., 3-2
Shinomiyabi-cho,Shinjuku-ku
Tokyo 162-0822
Japan

Mr Nath RAJIV
Secretariat - Forum Coordinator
Association of Indian Medical Device Industry (AIMED)
Gl-3 Ashoka Estate
Barakhamba Road
New Delhi 110001
India

Mrs Sumati RANDEO
Medical Technology Association of New Zealand (MTANZ)
PO Box 74116
Greenlane Central
Auckland 1546
New Zealand

Mr Herb RIBAND
EUROMED
Place Des Maires 2
Brussels 1150
Belgium

Mrs Sarah SMILEY
Advanced Medical Technology Association (ADVAMED)
701 Pennsylvania Ave, N.W., Suite 800
Washington, D.C. 20004-2654
United States of America

Dr Lindsay TAO
Medical Technology Association of Australia (MTAA)
Level 12, 54 Miller Street
North Sydney NSW 2060
Australia

Anne TRIMMER
Medical Technology Association of Australia (MTAA)
Level 12, 54 Miller Street
North Sydney NSW 2060
Australia

Ms Janet TRUNZO
Advanced Medical Technology Association (ADVAMED)
701 Pennsylvania Ave, N.W., Suite 800
Washington, D.C. 20004-2654
United States of America

Mr Zeger VERCOUTEREN
EUROMED
Place Des Maires 2
Brussels 1150
Belgium

Mr Rex WIDMER
COCIR
Diamant Building
Bd A. Reyers 80
Brussels 1030

INTERGOVERNMENTAL ORGANIZATIONS

EUROPEAN COMMISSION
Dr Isabelle DEMADE
Directorate General on Health and Consumers
Unit B2, Cosmetics and Medical Devices
45 Avenue d’Auderghem
Brussels 1040
Belgium

INTERNATIONAL ATOMIC ENERGY AGENCY
Mrs Joanna IZEWSKA
Nuclear Sciences and Applications
Vienna International Centre
Vienna 1400
Austria

Mr Graeme MORGAN
Chairman of AGaRT
Nuclear Sciences and Applications
Vienna International Centre
Vienna 1400
Austria

UNICEF
Mrs Wanda KREKEL
UNICEF Office for Thailand
19 Phra Atit Road, Banglumpoo
Bangkok 10200
Thailand

Mr Ludo SCHEERLINCK
Health Technology Center
UNICEF, Supply Division
Freehavn Uniceflpads #1
2100 Copenhagen
Denmark

Mr Sombat SIRIPATTANAKUL
UNICEF Office for Thailand
19 Phra Atit Road, Banglumpoo
Bangkok 10200
Thailand

UNOPS
Mr Ram TRIVEDI
UNOPS, UN Service Building, 2nd Floor
Rajadannem Nok Avenue
Bangkok 10200
Thailand
THE WORLD BANK
Mr. Ekkehard BETSCH
1818 H Street N.W., Msn G7-701
Washington D.C. 20433
United States of America

Dr. Ok PANNENBORG
Department of Health, Nutrition & Population
1818 H Street N.W.
Washington D.C. 20433
United States of America

WHO AFRICAN REGION
Dr. Nicholas ADJABU
Essential Health Technology
WHO Kenya Country Office
4th Floor, Ack Garden House
1St Ngong Avenue, Off Bishop Road
P.O. Box 45335-00100
Nairobi 100
Kenya

WHO PAN AMERICAN REGION
Pablo JIMENEZ
Regional Advisor in Radiological Health
Medicines and Technologies
Area of Health Systems based on Primary Health Care (HSS)
Pan American Health Organization Regional Office / WHO
525 23rd. St., N.W.
Washington, D.C. 20037
United States of America

WHO EASTERN MEDITERRANEAN REGION
Dr. Adham Rashad ABDEL-MONEIM
Health Systems and Services Development
WHO Regional Office for the Eastern Mediterranean
Abdel-Razzak Al-Sanhouri St., Nasr City, Cairo
Egypt

Mr. Kamel ABDUL RAHIM
Health Technology and Medical Devices
WHO Iraq Country Office
P.O. Box 3044
Amman 11821
Jordan

Mrs. Hashim ELMOUSAAD
WHO Jordan Country Office
Alal Al-Fasi 8 - Al-Shmisani
P.O. Box 811547
Amman 11181
Jordan

Dr. Iyad MOBAREK
WHO Jordan Country Office
P O Box 1332
Sweleh - Husam Eldin
Almufti Street 4B, Maysaloon Area
Amman 11910
Jordan

WHO EUROPEAN REGION
Mrs. Maria Hayde REYNOso
WHO Regional Office for Europe
Scherfigsgjæ 8
Copenhagen 2100
Denmark

WHO SOUTH-EAST ASIA REGION
Dr. San tee PLANBANGCHARANG
Regional Director
WHO Regional Office for South-East Asia
Indra Prastha Estate, Mahatma Gandhi Marg
New Delhi 110002
India

Dr. Soffia Osk MAGNUSSOTTIR
Department of Health Systems Development
Health Technology and Patient Safety
WHO Regional Office for South-East Asia
Indra Prastha Estate, Mahatma Gandhi Marg
New Delhi 110002
India

Dr. Geeta MEHTA
Health Systems Development
WHO Regional Office for South-East Asia
Indra Prastha Estate, Mahatma Gandhi Marg
New Delhi 110002
India

Dr. Manisha SHRIDHAR
WHO Regional Office for South-East Asia
Indra Prastha Estate, Mahatma Gandhi Marg
New Delhi 110001
India

Dr. Sombat THANPRASERTSUK
The Office of WHO Representative to Thailand
Permanent Secretary Bldg.
c/o Ministry of Public Health
Tiwannon Road
Nonthaburi 11000
Thailand

Mr. Stephane GUICHARD
Vaccine Supply and Quality Immunization and Vaccine Development
c/o Ministry of Public Health
Tiwannon Road
Nonthaburi 11000
Thailand

WHO WESTERN PACIFIC REGION
Mr. Paul ROGERS
Division of Health Sector Development
WHO Regional Office for the Western Pacific
P.O. Box 2932
Manila 1000
Philippines

Dr. Wiwat ROJANAPITHAYAKORN
WHO Mongolia Country Office
P.O.Box 663
Ulaanbaatar 13
Mongolia

WHO HEADQUARTERS
Dr. Margaret F.C. CHAN FUNG
Director-General

Dr. Ian Michael SMITH
Advisor to Director-General

20, Avenue Appia
1211 Geneva
Switzerland

DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS
Mr. Denis MAIRE
Technical Officer

DEPARTMENT OF LOGISTICS SUPPORT SERVICES
Mr. Richard PRESTON
Coordinator

HEALTH SYSTEMS AND SERVICES CLUSTER
Dr. Carissa F. ETIENNE
Assistant Director General
Health Systems and Services
Ms Sarah Catherine RUSSELL
Communications, Assistant Director General Office
Health Systems and Services Cluster

DEPARTMENT OF ESSENTIAL HEALTH TECHNOLOGIES
Ms Helena ARDURA GARCIA
Diagnostic Imaging and Medical Devices Unit

Ms Jennifer BARRAGAN
Diagnostic Imaging and Medical Devices Unit

Ms Deirdre DIMANCESCO
Diagnostic Imaging and Medical Devices Unit

Mr Bjorn FAHLGREN
Diagnostic Imaging and Medical Devices Unit

Dr Steffen GROTH
Director
Essential Health Technologies

Mrs Evelyn JIGUET
Essential Health Technologies

Dr Selma KHAMASSI
Injection Safety
Diagnostic Imaging and Medical Devices Unit

Mrs Divina MARAMBA
Essential Health Technologies

Mr Fernando PACHECO
Diagnostic Imaging and Medical Devices Unit

Mrs Irena PRAT
Diagnostic Laboratories Technologies Unit

Ms Karina REYES MOYA
Diagnostic Imaging and Medical Devices Unit

Dr Noboru TAKAMURA
Diagnostic Imaging and Medical Devices Unit

Mrs Adriana VELAZQUEZ BERUMEN
Coordinator
Diagnostic Imaging and Medical Devices Unit
Appendix G
Participant feedback survey results

Below is a summary of the results of a feedback survey given to participants. They were asked to rate the sessions, both plenary and parallel on a scale from 1 to 5 in three different categories:

1. Content was of interest to participant
2. Presenters were knowledgeable about the subject-matter
3. The session was engaging and interactive
The role of medical devices to improve health service delivery

Millennium Development Goals 4, 5 and 6

Meeting the needs

The convergence of eHealth and medical devices: implications for the future

Safe, accessible and affordable medical devices

Towards safe and appropriate radiation treatment

Safe medical devices for the patient, the health worker and the environment

WHO call for innovative technologies that address global health concerns

Health technology assessment, regulation, and management of medical devices when evaluating the needs

Assessment for innovative and emerging technologies

Pre-market approval including preclinical and clinical evaluation

Needs assessment: epidemiological needs, inventories, and medical device lists

Prioritization, selection, and harmonization

Equipment incorporation: selection, procurement, and donations

HTA of medical devices: national prioritization processes

Harmonization of regulation – challenges and benefits

Assessment and management a continuous process

The need for adverse event reporting and postmarket surveillance

Healthcare technology operation: training, safe use, and maintenance

The need for continuous HTA in developing countries and the role of international organizations
## Appendix H

### Voting results for the 42 proposed recommendations, by theme
(as percentage of total votes cast)

#### The role of medical devices to improve health service delivery

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Agreed (%)</th>
<th>Disagreed (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promote culture of safety in developing countries by adverse event reporting, and integrate patient safety concepts into the curriculum of medical professionals*</td>
<td>90%</td>
<td>10%</td>
</tr>
<tr>
<td>Highlight and share examples of appropriate technologies (locally produced, low prices, easy to use, durable and reliable) that succeeded in different national health care settings*</td>
<td>90%</td>
<td>10%</td>
</tr>
<tr>
<td>Use the infrastructure of teaching units and the guidelines already present for training of trainers and technicians on medical technologies</td>
<td>90%</td>
<td>10%</td>
</tr>
<tr>
<td>Enhance knowledge base of disease epidemiology, solutions and cost-effectiveness</td>
<td>90%</td>
<td>10%</td>
</tr>
<tr>
<td>Survey countries for successful/unsuccessful e-health/telemedicine projects*</td>
<td>90%</td>
<td>10%</td>
</tr>
<tr>
<td>Conduct cost benefit studies</td>
<td>90%</td>
<td>10%</td>
</tr>
<tr>
<td>Strengthen patient/community involvement in all medical devices processes (design, research, provision, etc.) to improve health outcomes and ensure that needs are met</td>
<td>90%</td>
<td>10%</td>
</tr>
<tr>
<td>Establish links between government and NGO projects and programmes</td>
<td>90%</td>
<td>10%</td>
</tr>
</tbody>
</table>

*Indicates recommended for support.
Safe, accessible and affordable medical devices

Ensure that properly trained personnel are in place at the time of installation of radiation medicine technology *

Plan carefully at the government level for any new installation including consideration of proper infrastructure for effective use of the technology and investment in staff training

Look at international recommendations to establish proper sharp waste management*

Facilitate the emergence of clear context-specific regulatory guidelines*

WHO: Continue producing technical specifications of medical devices and guidance on cost assessment

WHO: Foster cooperation between academia and industry

Member States: Find an appropriate way of phasing out the use of mercury

Conduct evidence-based comparison between mercury and digital equipment

Plan carefully at the government level for any new installation including consideration of proper infrastructure for effective use of the technology and investment in staff training

* Indicates actions that may require international cooperation.
Health technology assessment

WHO: Support developing countries to develop capacity, learning from countries with developed health technology assessment systems and considering different models

WHO: Promote health technology assessment as an integral part of health system research and strengthening, and assist developing countries in conducting health technology assessment*

WHO: Help Member States to identify tools for prioritizing devices by using the health technology assessment process*

Identify and adapt tool kits needed for health technology assessment and prioritize according to type, need and stage of development

WHO and other international organizations: Use experience of developed countries to build local capacity focusing on transparency for assessing and purchasing

Member States: Integrate continuous health technology assessment into the existing health system environment and health care system reforms

Urge health technology assessment agencies to collaborate with developing countries

WHO: Promote the value of continuous health technology assessment regarding medical devices in decisions to stakeholders in developing countries, policy-makers and industry representatives*

[Bar chart showing the percentage of agreement and disagreement for each statement]
The First WHO Global Forum on Medical Devices Context, outcomes and future actions

Health technology management

- **WHO: Support free access to nomenclature systems**
  
  - Agreed: 90%
  
- **WHO: Urge industry to tag medical devices with a nomenclature reference**
  
  - Agreed: 85%
  
- **WHO: Develop tools for needs assessment incorporating multiple dimensions (e.g., human resources, epidemiology, etc)**
  
  - Agreed: 80%
  
- **WHO: Provide up-to-date medical device lists to be functional/procedure and facility level-based**
  
  - Agreed: 75%
  
- Develop toolkit for life cycle cost of equipment and standardization of equipment
  
  - Agreed: 70%
  
- Provide case studies to show evidence of effectiveness of health technology management
  
  - Agreed: 65%
  
- **WHO: Develop decision-making guideline and tools to determine requirements for needs-driven procurement of technologies**
  
  - Agreed: 60%
  
- Develop and/or enhance training facilities for health technology managers
  
  - Agreed: 55%
  
- **WHO: Support and enhance the profile of health technology management and structures within ministries of health**
  
  - Agreed: 50%
  
- WHO: Provide up-to-date medical device lists to be functional/procedure and facility level-based
  
  - Agreed: 45%
  
- Develop toolkit for life cycle cost of equipment and standardization of equipment
  
  - Agreed: 40%
  
- Provide case studies to show evidence of effectiveness of health technology management
  
  - Agreed: 35%
  
- **WHO: Develop decision-making guideline and tools to determine requirements for needs-driven procurement of technologies**
  
  - Agreed: 30%
  
- Develop and/or enhance training facilities for health technology managers
  
  - Agreed: 25%
  
- **WHO: Support and enhance the profile of health technology management and structures within ministries of health**
  
  - Agreed: 20%
  
- WHO: Provide up-to-date medical device lists to be functional/procedure and facility level-based
  
  - Agreed: 15%
  
- Develop toolkit for life cycle cost of equipment and standardization of equipment
  
  - Agreed: 10%
  
- Provide case studies to show evidence of effectiveness of health technology management
  
  - Agreed: 5%
  
- **WHO: Develop decision-making guideline and tools to determine requirements for needs-driven procurement of technologies**
  
  - Agreed: 0%
  
- Develop and/or enhance training facilities for health technology managers
  
  - Disagreed: 100%
  
- **WHO: Support and enhance the profile of health technology management and structures within ministries of health**
  
  - Disagreed: 100%

WHO: Support and enhance the profile of health technology management and structures within ministries of health

WHO: Develop tools for needs assessment incorporating multiple dimensions (e.g., human resources, epidemiology, etc)

WHO: Provide up-to-date medical device lists to be functional/procedure and facility level-based

Develop toolkit for life cycle cost of equipment and standardization of equipment

Provide case studies to show evidence of effectiveness of health technology management

WHO: Develop decision-making guideline and tools to determine requirements for needs-driven procurement of technologies

Develop and/or enhance training facilities for health technology managers

WHO: Support free access to nomenclature systems

WHO: Urge industry to tag medical devices with a nomenclature reference

Health technology management
WHO: Facilitate opportunities for capacity building based on cooperation between regulatory authorities*

WHO: Facilitate capacity building for post-market surveillance and adverse event reporting in low-income countries

Promote an exchange system for information on regulatory action

WHO and Global Harmonization Task Force (GHTF): Support governments to have harmonized standards in different countries

Facilitate experience sharing and a meeting for device regulators every two years

WHO: Encourage international databank for adverse events in addition to national databases and exchange of information*

WHO and GHTF: Take lead in the use of medical device regulation for pre-market and post-market guidance*

GHTF: Promote more support to assist countries to develop harmonized mechanisms

WHO: Develop a programme for adverse event reporting on medical devices

* The top recommendations as voted for by participants within the individual sessions.
## Appendix I

### All recommendations suggested by forum participants

<table>
<thead>
<tr>
<th>Theme</th>
<th>Session title</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>The role of medical devices to improve health service delivery</td>
<td>MDGs 4, 5 and 6</td>
<td>Promote culture of safety in developing countries by adverse event reporting, and integrate patient safety concepts into the curriculum of medical professionals. Clinical practice guidelines must be evidence based and implementers should be part of the development process. Empower community and consumers to demand devices that conform to 1. 2. 3. above. Enhance knowledge base of disease epidemiology, solutions, cost-effectiveness. Identify ways to enhance acceptance and use of low cost, low-tech devices like condoms, safe syringes. Increase acceptability of consumers in the use of self care devices. Select medical devices from CPGs. The CPGs should be the basis for the selection of medical devices.</td>
</tr>
<tr>
<td>The role of medical devices to improve health service delivery</td>
<td>Meeting the needs</td>
<td>Highlight and share examples of appropriate technologies (locally produced, low prices, easy to use, durable and reliable) that succeeded in different national health care settings. Use the infrastructure of teaching units and the guidelines already present for training of trainers and technicians on medical technologies. Investigate available resources (within the organization) that addresses needs assessment and prioritization. These resources have to be collated and disseminated for member states to benefit from. Conduct a survey on availability and accessibility of medical devices in different countries. Develop guidelines on different healthcare technology aspects, including success stories. Develop, validate and disseminate a framework for integrated healthcare needs assessment. Ensure that technology development does not interfere with healthcare delivery resources. Look into ways of increasing the role of industry, patient organization and others in terms of needs assessment. Strengthen patient/community involvement in all medical devices processes (design, research, provision, etc.) to improve health outcomes and ensure that needs are met.</td>
</tr>
<tr>
<td>The convergence of eHealth and medical devices: implications for the future</td>
<td>The convergence of eHealth and medical devices: implications for the future</td>
<td>Survey countries for successful/unsuccessful e-health/telemedicine projects. Cost/benefit studies. Develop stakeholders taskforce to help align capacity building for global health needs. Focus on appropriate patient-centric record keeping. Good practices/appropriate technologies. Link between government and NGO projects. Open source culture. Study or guideline to understand how to reduce telecommunication costs (infrastructure and bandwidth service).</td>
</tr>
</tbody>
</table>
| Safe, accessible and affordable medical devices | Towards safe and appropriate radiation treatment

- Ensure that properly trained personnel are in place at the time of installation of radiation medicine technology.
- Plan carefully at the government level for any new installation including consideration of proper infrastructure for effective use of the technology and investment in staff training.
- To include comprehensive technology radiotherapy packages.
- To ensure access to palliative care centers in provincial/district hospitals supported by telemedicine.
- To ensure the application of International Radiation safety Standards (BSS) in the medical field.
- To facilitate the human resources development as technology evolves.
- WHO to continue producing technical specifications of medical devices and guidance on cost assessment. |

| Safe medical devices for the patient, the health worker and the environment

- Look at international recommendations to establish proper sharp waste management.
- Maintain sphygmomanometer for calibration.
- Countries should find an appropriate way of phasing out mercury.
- Evidence based comparison between mercury and digital equipment.
- There should be a legislation to regulate medical practices.
- Phasing out mercury needs to be accompanied with proper training of healthcare workers.
- Look at options to sterilize plastic syringes before recycling.
- After proper evaluation eliminate all mercury devices. |

| Safety and innovative technologies that address global health concerns

- Facilitate the emergence of clear context-specific regulatory guidelines.
- WHO to lobby for funding of early research and promote.
- Engage end users in co-creative design process within an interdisciplinary setting.
- Foster cooperation between academia and industry.
- Give more consideration to maintenance and transparency.
- Promote use of HTA information in the innovation process.
- Provide guidance/information on local conditions.
- Recommend to industry to make devices that help patients to help themselves, in the perspective of lack of manpower in health care.
- WHO to facilitate adoption of technology to local conditions. |

| Health technology assessment (HTA) | Assessment for innovative and emerging technologies

- WHO: Promote health technology assessment as an integral part of health system research and strengthening, and assist developing countries in conducting health technology assessment.
- WHO should promote links between MS and HTA institutions.
- HTA designed for MD. Life cycle, . . .
- Identify and adapt necessary tool kits needed for HTA and be able to prioritize according need, and stage of development.
- More coordination with MS and other organization to allocate funds to conduct HTA in developing countries (cost and clinical effectiveness).
- Urge HTA institutions to collaborate with manufacturers & business communities to work in developing countries.
- WHO should work closely with MS to identify existing health services research institutions to support MS to identify useful technologies. |

| HTA of medical devices: national prioritization processes

- WHO: Help Member States to identify tools for prioritizing devices by using the health technology assessment process.
- Is there a need of a global device register? Synergies must be done?
- Careful management of evidence to restrict access of interventions based on evaluation?
- Urging the system to do more comparative effective analyzing.
- WHO and international organizations to use experience of developed countries to build local capacity focusing on transparency for assessing and purchasing.
- WHO learning from NICE recognizing Pharmaceutical are different from MD and proceed consequently.
- WHO taking account of interoperability of emerging devices interoperability roadmap.
- WHO works with international agencies and HTA to develop best practices and a global register. |

| The need for continuous HTA in developing countries and the role of international organizations

- WHO: Support developing countries to develop capacity, learning from countries with developed health technology assessment systems and considering different models.
- WHO: Promote the value of continuous health technology assessment regarding medical devices in decisions to stakeholders in developing countries, policy-makers and industry representatives.
- WHO: support DC for Context specific HTA focusing for example on primary health care.
- All stakeholders including patients should be involved in priority setting.
- Aid is an important component, HTA is not only for pharmaceuticals. HTA should be used for MD with appropriate methodology.
- Member Countries: HTA should be integrated into/within the existing health system environment and health care system reforms. |
| Health technology management (HTM) | Needs assessment: epidemiological needs, inventories, and medical device lists | WHO: Support free access to nomenclature systems.  
WHO: Develop tools for needs assessment incorporating multiple dimensions (e.g. human resources, epidemiology, etc.).  
WHO to provide up to date medical device lists to be functional/procedure and facility level based.  
Review and update WHO HTF tool improving user-friendliness and to be made suitable for multiple health settings.  
WHO to advocate for greater focus of MS MoH on medical device issues (including use of WHO e-centre).  
WHO to provide guidance on distribution of budgetary resources for medical devices at 3 levels of care.  
WHO to support access to information on medical device life-cycle and other costs. |
| --- | --- | --- |
| Equipment incorporation: selection, procurement, and donations | WHO: Develop decision-making guideline and tools to determine requirements for needs-driven procurement of technologies.  
WHO to produce guidelines for equipment donation and must ensure they are fairly new and the consumables must be supplied or source of supply must be identified.  
Donors to be made responsible for the equipment they donate.  
Essential list should include specification.  
Guidelines for procurement of pre-owned equipment.  
Including contracting and jurisdiction clauses in the guidelines for sourcing.  
Toolkit for lifecycle cost of equipment and standardization of equipment.  
Training facility for HTM managers.  
WHO to develop generic specification to support procurement.  
WHO to produce essential list of MD for functional specialties and intervention not just by level of health care. |
| Healthcare technology operation: training, safe use, and maintenance | WHO: Urge industry to tag medical devices with a nomenclature reference.  
WHO promote public awareness of safe/ethical clinical practice.  
Case studies to show evidence of effectiveness of HTM.  
Develop expert network to support implementation of guidelines in LIC.  
WHO to build improved information exchange mechanisms.  
WHO to develop training program for MEAL in rural areas.  
WHO to promote good management practice with M&E tool.  
WHO to raise profile of HTM and structures within MoH.  
WHO to urge Member States to develop new approach and take responsibility for medical devices and asset management.  
WHO to urge MS to establish minimum HTM budgets. |
| Health technology regulation | Pre-market approval including preclinical and clinical evaluation | WHO: Facilitate opportunities for capacity building based on cooperation between regulatory authorities.  
Promote an exchange system for information on regulatory action.  
Facilitate experience sharing and meeting for device regulators every 3 years.  
WHO to propose a checklist and standards for medical device validation.  
WHO to propose a global database that regulators could consult.  
WHO to facilitate cooperation between all stakeholders in capacity building.  
WHO to put priority on post market surveillance while prioritizing resources.  
Promote understanding that differences between different settings may justify local requirements. |
| The need for adverse event reporting and postmarket surveillance | WHO: Facilitate capacity building for post-market surveillance and adverse event reporting in low-income countries.  
WHO: Encourage international databank for adverse events in addition to national databases and exchange of information.  
WHO coordinating conferences of regulators of medical devices (2-3 years).  
WHO should encourage a PMS plan following the first entry in the market of the medical device.  
WHO to develop a programme for adverse event reporting on medical devices.  
WHO to develop guidelines encouraging healthcare workers reporting on adverse events in a “blame free” culture. |
| Harmonization of regulation - challenges and benefits | WHO and GHTF: Take lead in the use of medical device regulation for pre-market and post-market guidance.  
WHO to support a transparent easily verifiable database methods.  
Continued close relationship with Asian Harmonization Working Party.  
Contribution to regional training.  
Definition of manufacture database.  
Develop liaison with other regions.  
GHTF to promote more support to assist countries to develop harmonized mechanism in particular areas beyond WHO justification.  
AOUs with key bodies eg. ISO, IEC.  
WHO and GHTF to convince the government to accept global harmonized guidance in different countries.  
WHO puts them together on a life cycle (holistic) approach. |
Appendix J

Draft programme summary for the second WHO Global Forum on Medical Devices

Date: April – June 2012
Venue: TBD

Draft Objectives
1. To share evidence of best practices in the assessment, management and regulation of medical devices that have improved access to safe, quality medical devices.
2. To demonstrate the use of appropriate and innovative technologies that respond to global health priorities.
3. To present the outcomes of the implementation of the World Health Assembly resolution on health technologies (WHA60.29) five years after its approval.

Outcomes
1. Provision and dissemination of evidence on improving access to safe and effective medical devices as well as on positive health outcomes directly or indirectly related to medical devices.
2. Development of key recommendations that stakeholders will implement over the following 2 years.

Overview of Draft Scientific Programme
With the exception of the first session, each of the sessions below would consist of presentations by designated number of Member States on best practices, experiences, and their measured impact on health outcomes. When appropriate, international organizations would also have the opportunity to present issues surrounding their topic of interest. The session would include sufficient time for discussion and development of recommendations.

<table>
<thead>
<tr>
<th>Key points to be addressed</th>
<th>Key points to be addressed</th>
<th>Pertinent paragraph of WHA 60.29</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes from the First Global Forum on Medical Devices</td>
<td>Status on the execution of the short- and long-term actions</td>
<td>N/A</td>
</tr>
<tr>
<td>Information on health technologies</td>
<td>Presentation of available country data and statistics</td>
<td>to collect, verify, update and exchange information on health technologies, in particular medical devices, as an aid to their prioritization of needs and allocation of resources</td>
</tr>
<tr>
<td>National strategies/ plans/ policies on health technologies</td>
<td>Presentations on implementation of strategies, plans or policies by a biomedical engineer or health technology assessment expert</td>
<td>to formulate as appropriate national strategies and plans for the establishment of systems for the assessment, planning, procurement and management of health technologies in particular medical devices, in collaboration with personnel involved in health-technology assessment and biomedical engineering</td>
</tr>
<tr>
<td>Regulation for medical devices</td>
<td>Presentations on the results of implementing a regulatory framework and process</td>
<td>to draw up national or regional guidelines for good manufacturing and regulatory practices, to establish surveillance systems and other measures to ensure the quality, safety and efficacy of medical devices and where appropriate participate in international harmonization</td>
</tr>
<tr>
<td>National institutions on health technology</td>
<td>Description of the organization, processes and impact of a national unit on health technologies</td>
<td>to establish where necessary regional and national institutions of health technology, and to collaborate and build partnerships with health care providers, industry, patients’ associations and professional, scientific and technical organizations</td>
</tr>
</tbody>
</table>

Pertinent paragraph of WHA 60.29: N/A
Medical devices adapted to national settings and needs

- Presentations on list of medical devices, the required infrastructure for use of the tool, and outcomes from using the tool
- Presentations on how countries determine their needs and ensure access to medical devices.
- Presentations on medical device needs determination in a specific setting.
- Presentations on the implementation of health technology policies
- Outcome of use of WHO clearinghouse tool

Presentation of guidelines, tools and glossary developed by WHO

- Status of the implementation of documents and tools
- Discussion on open work and forward action

Determining national needs

- Presentations on list of medical devices, the required infrastructure for use of the tool, and outcomes from using the tool
- Status of the implementation of documents and tools
- Discussion on open work and forward action

Methodological tools

- Presentations on list of medical devices, the required infrastructure for use of the tool, and outcomes from using the tool
- Status of the implementation of documents and tools
- Discussion on open work and forward action

Policies on health technologies for priority diseases

- Presentations on list of medical devices, the required infrastructure for use of the tool, and outcomes from using the tool
- Status of the implementation of documents and tools
- Discussion on open work and forward action

WHO clearinghouse on health technologies

- Presentations on list of medical devices, the required infrastructure for use of the tool, and outcomes from using the tool
- Status of the implementation of documents and tools
- Discussion on open work and forward action

Appropriate health technologies

- Presentations on list of medical devices, the required infrastructure for use of the tool, and outcomes from using the tool
- Status of the implementation of documents and tools
- Discussion on open work and forward action

Also being considered are parallel workshops on some or all of the following topics held over the course of one to two days.

<table>
<thead>
<tr>
<th>Workshop Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>How to develop a health technology policy</td>
</tr>
<tr>
<td>Uses of medical device nomenclature</td>
</tr>
<tr>
<td>How to use needs assessment tools</td>
</tr>
<tr>
<td>Resources for developing effective procurement systems</td>
</tr>
<tr>
<td>How to develop and enforce donation guidelines</td>
</tr>
<tr>
<td>How to develop an effective maintenance programme</td>
</tr>
<tr>
<td>Guidance on medical devices waste management</td>
</tr>
<tr>
<td>Economics of medical devices</td>
</tr>
<tr>
<td>How to perform pre-market approval</td>
</tr>
<tr>
<td>How to develop post-market surveillance programs</td>
</tr>
<tr>
<td>How to create a health technology assessment unit</td>
</tr>
<tr>
<td>How to evaluate appropriate, innovative medical devices</td>
</tr>
<tr>
<td>How to create or improve a health technology unit within a MoH</td>
</tr>
<tr>
<td>How to set priorities for procedures, using medical devices</td>
</tr>
<tr>
<td>How to define training, capacity building for human resources</td>
</tr>
</tbody>
</table>
Department of Essential Health Technologies
World Health Organization
20 Avenue Appia
CH-1211 Geneva 27
Switzerland
Tel: +41 22 791 1239
E-mail: medicaldevices@who.int
http://www.who.int/medical_devices/en/